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ABSTRACT 
 During the mid-1900’s, early anti-depressants were developed to increase levels of 
catecholamines within the brain, leading to the theory that depression symptomology was a result 
of an imbalance of neurotransmitters within the brain. To date, the catecholamine theory of 
depression is still held to be the prevailing theory as selective serotonin reuptake inhibitors being 
the most commonly prescribed anti-depressants. However, the incidence of depression is still 
rising with a vast amount of patients failing to respond to current treatments, and with this 
knowledge, additional theories of the neurobiology of depression have arisen over the past 30 
years. A leading theory is Kynurenine Pathway activation in relation to inflammation- or stress-
induced depression-like behaviors. There has been a tremendous amount of data connecting 
activated immune system (or hypothalamic-pituitary-adrenal axis), increased kynurenine 
production and depression symptomology. Thus, understanding the factors that activate this 
pathway, as well as determining a relationship between anti-depressants and regulation of the 
Kynurenine Pathway, is an important next step in understanding the complex etiology of 
depression. My work has focused on 1) describing interactions between inflammation and stress 
to accentuate the expression of rate-limiting enzymes (indoleamine/tryptophan-2,3-dioxygenase: 
DOs) that metabolize the essential amino acid tryptophan to kynurenine, 2) detailing a novel 
interaction between galectins and interferon-gamma to accentuate DO expression within the 
brain, and finally 3) discuss the ability of current anti-depressant desipramine to block these 
interactions and attenuate DO expression within the brain and periphery as a possible new 
mechanism by which anti-depressants may be working to reduce depression symptomology. 
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CHAPTER 1: Introduction 
1.1 Inflammation  
 The body responds to stimuli (i.e. infection or damage) by generating an inflammatory 
response: increasing pro-inflammatory cytokine levels including interleukin (IL)-1β, IL-6, tumor 
necrosis factor (TNFα), and interferons (IFNs) alpha and gamma. These cytokines are proteins 
necessary to guide immune cell activity to fight the inflammatory agent or aide in wound 
healing. However, data support the idea that elevated cytokines may be responsible for 
deleterious effects as well. Increases in inflammatory markers such as IL-1β, C-reactive protein 
(CRP), IL-6, and TNFα have been linked with multiple psychiatric conditions including bipolar 
disorder, depression, and schizophrenia (2).  
In both human and rodent models, sickness behavior occurs when pro-inflammatory 
cytokines are elevated following inflammatory insult. Cytokines cause changes in neuronal 
circuits that decrease goal-directed or reward behavior (3), increase sensitivity to pain, reduce 
general activity, reduce food intake, reduce body weight and cause fever. Once the initial 
sickness response begins to wane and locomotor activity returns to normal, depression-like 
behaviors remain (4). These cytokine-mediated events also occur in humans. Patients receiving 
IFNimmunotherapy to fight Hepatitis C or cancer initially experience sickness behavior, then 
up to 45% of these patients report depression-like symptoms (5-7). Additionally, healthy 
volunteers when injected with bacterial endotoxin (lipopolysaccharide, LPS), develop 
depression-like behaviors following a sickness response and elevated peripheral cytokines (8). 
Extensive research has been reported on the ability of an inflammatory challenge to induce a 
depression-like phenotype with rodent models. Like the human studies, administration of LPS to 
rodents evokes cytokine expression followed by a sickness response. Depression-like behaviors 
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such as despair (increased immobility during tail suspension test, TST) and anhedonia (decreased 
sucrose preference) are evident following an inflammatory challenge (4, 9-15).  
1.2 Stress 
Glucocorticoids (GCs) are hormones released following hypothalamic-pituitary-adrenal 
(HPA) axis activation. These hormones play a pivotal role in regulating immune and 
neuroendocrine responses and are critical in maintaining homeostasis within the body (16). The 
GCs corticosterone in rodents/cortisol in humans bind to both the glucocorticoid receptor (GR) 
and mineralocorticoid receptor (MR) with varying affinities. Aldosterone (Aldo) binds to the 
MR, which plays a role in maintaining basal activation of the HPA axis (17). The hippocampus 
is a prime target for glucocorticoid effects (18); MRs have been shown to be highly concentrated 
in the hippocampus (17), while GRs are distributed throughout the brain, although still found at 
high concentrations within the hippocampus (17, 19). Complicating the matter further, MRs can 
be occupied by either mineralocorticoids (MCs) such as Aldo or GCs (cortisol/corticosterone), 
with GCs being 100–1000 times more abundant than mineralocorticoids within the circulation.  
Dysregulation of the stress response has been associated with multiple psychiatric 
disorders such as PTSD (20), depression (21), and schizophrenia (22). Depressed patients have 
increased concentrations of cortisol in plasma, urine, and cerebrospinal fluid (21), and elevated 
circulating Aldo (23, 24), most likely due to altered HPA axis activity. Administration of Aldo, 
Cort, and Dex or subjecting animals to stress induces anxiety and depression-like behaviors, 
despair and anhedonia, in rodents (25-29). Similarly, patients suffering from hyperaldosteronism 
(Conn’s syndrome) have been shown to display depression-like symptoms (30, 31), and further 
research shows that there’s an increase of Aldo during stress of animals (19, 25, 32) and humans 
(19, 33). Approximately 54% of patients suffering from hypercortisolemia (Cushing’s disease) 
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suffer from major depression; with increased depression symptom severity associated with 
higher cortisol levels (34).  
1.3 Tryptophan Metabolism 
 Tryptophan, an essential amino acid, is used in the body for multiple purposes; it is 
regularly used in the synthesis of proteins, can be metabolized into the neurotransmitter serotonin 
or metabolite kynurenine, and used as a substrate for NAD/NADP production. Interestingly, after 
tryptophan’s necessary function in protein synthesis, almost 90% of tryptophan metabolism is to 
synthesize kynurenine while only 3% of tryptophan is used to synthesize serotonin (only 1% in 
the brain) (35). Historically, depression symptoms are attributed to decreased serotonin 
synthesis, however research is now focused on tryptophan metabolism away from serotonin and 
towards the Kynurenine Pathway (Fig. 1). Indoleamine-2,3-dixoxygenase 1 (Ido1), Ido2, and 
tryptophan-2,3-dioxygenase 2 (Tdo2) are the three rate-limiting enzymes that metabolize 
tryptophan to intermediate N-formyl-kynurenine, which is then hydrolyzed to kynurenine. 
Cytokines (the most potent being IFN) can increase expression of Ido1 and Ido2, while stress 
hormones can increase Tdo2 expression. Kynurenine can then be metabolized by kynureninase 
(Kynu, generating anthranilic acid), kynurenine 3-monooxygenase (KMO, generating 3-
hydroxykynurenine; 3-HK), or kynurenine aminotransferases (Kat2, generating kynurenine acid 
(KynA)). 3-HK is metabolized to 3-hydroxyanthranilic acid (3-HANA) by Kynu, which is then 
metabolized by 3-Hydroxyanthranilic acid oxygenase (Haao) to 2-amino-3-carboxymuconic-6-
semialdehyde, which can either be metabolized to quinolinic acid (QuinA) or picolinic acid (36). 
QuinA is then metabolized by quinolinic acid phosphoribosyltransferase (Qprt), yielding 
nicotinic acid mononucleotide (NAD) and further metabolic product NAD+, necessary to 
generate energy throughout the body and to battle inflammatory assault.  
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Figure 1. Tryptophan metabolism pathway.  
The two main neuroactive metabolites QuinA and KynA have been implicated in 
glutamatergic dysregulation through modulation of N-methyl-D-aspartate receptor (NMDA-R) 
activity (37, 38). QuinA is thought to induce neurotoxicity mediated by NMDA-R activation and 
promote the generation of free radicals (36). KynA blocks excitatory 
neurotransmission/excitotoxic injury, is anticonvulsant, and is a competitive antagonist of the 
NMDA-R and non-competitive antagonist of the alpha7 nicotinic acetylcholine receptor (36, 39). 
The properties of KynA (neuroprotective) and QuinA (excitotoxic) in the brain suggest that 
kynurenine metabolites may play a role in the pathophysiology and etiology of neurological 
conditions (36) and deviation from basal levels of these two metabolites could directly impact 
brain health. Indeed, there are increased QuinA and KynA levels in the CSF following traumatic 
brain injury (40) and amyotrophic lateral sclerosis (41, 42) patients, increased QuinA levels in 
IFN-treated Hepatitis C patients (43, 44), (with QuinA levels correlating to severity of 
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symptoms (43)), increased KynA in post-mortem brain tissue of individuals diagnosed with 
schizophrenia (45) and in CSF of patients diagnosed with bipolar disorder (46), and elevated 
QuinA in CSF of patients that correlated with suicide intents (47). 
1.4 DO and Behavior 
As the neuroactive metabolites are strongly associated with multiple disorders, studies 
investigating the role of Ido1, Ido2, and Tdo2 to impact behavior are critical. Some work has 
been done to determine the role of Ido1 in animal behavior; very little work has been performed 
describing the influence of Ido2 and Tdo2. Eliminating Ido1 activity using a genetic knockout 
(Ido1
KO
 mice) or blocking activity by administration of 1-methyltryptophan (1-MT, an inhibitor 
of both Ido1 and Ido2 enzymatic activity (48)) are common models used to define Ido1's role in 
animal behavior and immune function. Ido1
KO
 mice display normal dendritic cell development 
and functional characteristics (49). Ido1 deficiency, assessed in both Ido1
KO
 and 1-MT treated 
mice, protects mice against LPS-mediated endotoxin shock (50) and decreases sensitivity to 
neurotoxicity induced by QuinA (51). In both intraperitoneal Bacillus Calmette–Guérin (BCG) 
infected and LPS intracerebroventricular treated mice, both 1-MT administered and Ido1
KO
 
animals were protected from helplessness/despair depression-like behaviors (immobility during 
TST or forced swim test (FST)) (11, 14). Both Ido1
KO
 and Ido2
KO
 mice have deficits in 
oxazolone–induced Kyn/KynA-mediated T-cell maturation to the immunosuppressive Treg 
phenotype (52). Despite a similar anti-inflammatory role is these models, in a contact 
hypersensitivity model, cytokine expression was suppressed in Ido2
KO
 mice compared to both 
Ido1
KO
 and wild-type (WT) control mice. Similarly, in a rheumatoid arthritis model, it was also 
shown that Ido2, not Ido1, was necessary for the development of arthritic symptoms, as Ido2
KO
 
mice displayed decreased inflammation in the joint shown by decreased cytokine levels (53). 
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Interestingly, Tdo2
KO
 mice seem to have decreased anxiety in the elevated plus maze as well as 
increased neurogenesis in the hippocampus (54, 55). 
Following Toxoplasma gondii infection and dexamethasone administration, there is 
significant neuroinflammation as well as significantly increased plasma IFN levels and 
increased IFN, Ido1 and Ido2 expression within the brain (56). Similarly, these mice displayed 
increased immobility during both FST and TST and had decreased sucrose preference (56). 
Together these data connect Toxoplasma gondii infection, increased brain IFN and Ido 
expression and enhanced depression-like behaviors. During Japanese encephalitis infection, Ido1 
expression within the brain increased over time and correlated with clinical signs of viral disease 
progression, suggesting a relationship between brain Ido1 expression and severity of 
neurological symptoms seen after infection (57). Similarly, viral mimetic poly I:C and BCG 
induces neuroinflammation, Ido expression within the brain and depression-like behaviors in 
rodents (12, 58). 
These studies suggest that Ido1, Ido2, and Tdo2 may play distinct roles in animal 
behavior, however the distinct roles of Ido1, Ido2, and Tdo2 in the brain in relation to 
depression-like behavior is still unknown. 
1.5 DO Transcripts 
 Blocking Ido activity seems like an effective way to decrease inflammation-induced 
depression-like behavior, the pharmacological inhibitor of Ido activity, 1-MT, is also currently 
being tested in patients with cancer. 1-MT may have additional actions independent of its ability 
to block Ido activity, and this prompts the need for additional, more potent and specific Ido 
inhibitors (59). The idea of creating more specific inhibitory effects is exciting given the 
existence of multiple Ido1 and Ido2 variants, which suggests that individual mRNA transcripts 
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may be implicated in the induction of inflammation-induced depression-like behavior, and thus, 
blocking specific transcripts could allow for more precise control than blocking overall Ido 
activity. One manuscript describes expression of three Tdo2 transcripts within the mouse brain 
during development. This is the first manuscript to suggest that differential regulation of Tdo2 
transcripts could play a role in postnatal brain development (60). Soon after, another manuscript 
described Ido1 and Ido2 transcripts found in both human and mouse mesenchymal and neural 
stem cells and multiple tissues, including brain (61). It was the first manuscript to suggest that 
only certain transcripts were detectable in the brain, while other transcripts could be induced by 
inflammatory mediators (i.e. IFN) in a tissue-specific manner (61). We followed this work to 
identify and describe regulation for multiple Ido1 and Ido2 transcripts in the brain. 
1.6 Overlapping Pathways 
Although inflammation or stress can induce depression-like behaviors, only recently has 
there been work suggesting that these two pathways synergize to induce depressive-symptoms 
(62). In a study of suicide attempters, there was a significant association between inflammatory 
markers (IL-6 and CRP), psychological stress, and suicidal risk (63). In chronically stressed 
mice, a single low-dose of LPS accentuated depression-like behaviors (64). Similarly, repeated 
LPS administration to chronic mild stress mice accentuated depression-like behavior (65). 
Although no mechanism was given, my dissertation research suggests that inflammation and 
stress could interact to accentuate expression of the DOs and induce the Kynurenine Pathway.  
Galectins (Gals) are B-galactoside-binding lectins which can interact extracellularly with 
cell-surface glycans on multiple immune cells to exert their immunomodulatory capabilities (66). 
There are three distinct groups of Gals, classified by differences in the carbohydrate-recognition 
domain (CRD). For example, Gal-1 is a member of the proto-type group which only has one 
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CRD, while Gal-3 is part of the chimera-type group which has one CRD connected to a non-
lectin region, consisting of proline and glycine rich sections. Finally, Gal-9 is a member of the 
tandem repeat-type group which is made up of two distinct CRDs connected by a linker. 
Although Gal-1, Gal-3 and Gal-9 are members of different groups based on CRD content, these 
three Gals are also associated with neuroinflammation (67-69) and multiple disorders including 
multiple sclerosis (MS) (70, 71) and amyotrophic lateral sclerosis (ALS) (69). Although there is 
research suggesting that Gals may modulate neuroinflammation, there is no work suggesting 
overlap between Gals, the Kynurenine Pathway, or depression. Thus, I investigated the ability of 
neuroinflammation and Gals to interact to accentuate DO expression and induce the Kynurenine 
Pathway. 
1.7 Clinical Relevance 
 Many of the most commonly prescribed anti-depressants are selective serotonin reuptake 
inhibitors, such as fluoxetine, or serotonin/norepinephrine reuptake inhibitors, such as 
desipramine (Desip). Although the main purpose of anti-depressants was originally to increase 
neurotransmitter levels within the brain, it has been postulated that anti-depressants may have 
additional mechanisms of action. However, there has been no work suggesting that anti-
depressants alter DO expression in the brain or periphery, and thus, it would be important to 
determine if an anti-depressant could decrease inflammation- and/or inflammation x 
corticosteroids or Gal-9- induced Ido1 and Ido2 expression in the brain. Discovering a novel 
mechanism by which anti-depressants may affect patients is of critical importance as it could 
help with the design of future therapeutics. Physicians choosing medications for their depressed 
patients is considered an art, not necessarily based in science, as it is unclear why certain patients 
do or do not respond to different anti-depressants. Further defining anti-depressant action within 
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the brain may reveal that patients battling cancer or Hepatitis C may respond better to an anti-
depressant that does or does not alter DO expression. Although too soon to be sure, this is 
definitely an exciting path for the future. 
 In addition to inflammation-induced depression-like behaviors, Kynurenine Pathway 
activation (specifically DOs) is well associated with other neurological and autoimmune 
disorders. Increased Ido1 expression is found in the brain of a murine model of Huntington’s 
disease (72), while an increased kynurenine:tryptophan ratio within plasma is found in patients 
with Huntington’s disease (73). Similarly, in mouse models of Alzheimer’s disease, there was 
increased Ido1 and Tdo2 expression in the brain (74) and furthermore, an Ido inhibitor was able 
to decrease Ido activity as well as decreasing amyloid plaque formation (75). There are also 
higher levels of Ido1 and Tdo2 positive cells within the brain of Alzheimer’s disease patients 
(74, 76, 77). As Ido1 and Ido2 play a role in regulating inflammation, there is a strong 
connection between activated Kynurenine Pathway and both multiple sclerosis (MS) and 
amyotrophic lateral sclerosis (ALS). Patients with relapse-remitting MS have higher expression 
of Ido1 in peripheral blood mononuclear cells (PBMCs) (78), while patients with ALS have 
increased microglial Ido expression as well as increased serum kynurenine and quinolinic acid 
levels (79). There is a strong connection between Kynurenine Pathway activation and multiple 
neurological/ autoimmune diseases, suggesting that independent of inflammation-induced 
depression, understanding the regulation of the DOs may be crucial for determining the etiology 
of a variety of disorders. 
1.8 Conclusion 
As depression is predicted to become the number one major disease burden in the US by 
2030, there is an urgent need to define the underlying mechanisms responsible for MDD. One 
potential, under-appreciated mechanism to consider is the Kynurenine Pathway, which can be 
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induced by inflammatory mediators and stress hormones to produce neuroactive metabolites. 
Thus, my dissertation research is focused on the relationship between factors associated with 
depression (i.e. inflammation and stress) to discover overlapping pathways that may modulate 
the rate-limiting enzymes of this pathway to help define new therapeutic targets for anti-
depressant treatment and to better understand the mechanism behind current anti-depressant 
treatments.   
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CHAPTER 2:  Interactions between inflammatory mediators and corticosteroids regulate 
transcription of genes within the Kynurenine Pathway in the mouse hippocampus
1
 
 
2.1 Abstract  
Increased tryptophan metabolism towards the production of kynurenine via 
indoleamine/tryptophan-2,3-dioxygenases (DOs: Ido1, Ido2 and Tdo2) is strongly associated 
with the prevalence of major depressive disorder in patients and the induction of depression-like 
behaviors in animal models. Several studies have suggested that activation of the immune system 
or elevated corticosteroids drive DO expression, however, mechanisms linking cytokines, 
corticosteroids and DOs to psychiatric diseases remain unclear. Various attempts have been 
made to correlate DO gene expression within the brain to behavior, but disparate results have 
been obtained. We believe that discrepancies arise as a result of the under-recognized existence 
of multiple mRNA transcripts for each DO. Unfortunately, there are no reports regarding how 
the multiple transcripts are distributed or regulated. Here, we used organotypic hippocampal slice 
cultures (OHSCs) to directly test the ability of inflammatory and stress mediators to 
differentially regulate DO transcripts. OHSCs were treated with pro-inflammatory mediators 
(interferon-gamma (IFN, lipopolysaccharide (LPS) and polyinosine-polycytidylic acid (pI:C)) 
with or without corticosteroids (dexamethasone (Dex: glucocorticoid receptor (GR) agonist), 
aldosterone (Aldo: mineralocorticoid receptor (MR) agonist), or corticosterone (Cort: GR/MR 
agonist)). IFN induced Ido1-full length (FL) and Ido1-variant (v) expression, and surprisingly, 
Dex, Cort and Aldo interacted with IFN to further elevate expression of Ido1, importantly, in a 
                                                
1 Adapted from the published version in the Journal of Neuroinflammation (renumbered figures and formatting): 
Brooks AK, Lawson MA, Smith RA, Janda TM, Kelley KW, McCusker RH. Interactions between inflammatory 
mediators and corticosteroids regulate transcription of genes within the Kynurenine Pathway in the mouse 
hippocampus. J Neuroinflammation 2016, 1:98. 
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transcript dependent manner. IFN, LPS and pI:C increased expression of Ido2-v1 and Ido2-v3 
transcripts, whereas only IFN increased expression of Ido2-v2. Overall Ido2 transcripts were 
relatively unaffected by GR or MR activation. Naïve mouse brain expresses multiple Tdo2 
transcripts, Dex and Cort induced expression of only one of the three Tdo2 transcripts (Tdo2-FL) 
in OHSCs. These results establish that multiple transcripts for all three DOs are expressed within 
the mouse hippocampus, under the control of distinct regulatory pathways. These data identify a 
previously unrecognized interaction between corticosteroid receptor activation and inflammatory 
signals on DO gene expression, which suggest that corticosteroids act to differentially enhance 
gene expression of Ido1, Ido2 and Tdo2.  
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2.2 Introduction 
The lifetime prevalence of major depressive disorder (MDD) is almost 15 % (80) with 
nearly 10 % of the USA population taking antidepressants on any occasion (81). Within the 
general population, prevalence is 5 - 10 times higher in patients with a known medical illness 
(82), particularly when this medical illness is a chronic inflammatory condition (82). For 
example, people with multiple sclerosis have a prevalence rate of MDD up to 50% (83). Over the 
past 20 years, an association between the immune system and MDD has been clearly established. 
Studies have shown that patients with MDD have elevated levels of immunomodulatory factors 
(pro-inflammatory cytokines) within the circulation and increased expression of pro-
inflammatory cytokines in the central nervous system, neuroinflammation (6). During chronic 
administration of the pro-inflammatory cytokine IFN to patients with Hepatitis C or malignant 
melanoma, up to 45 % of patients eventually exhibit elevated symptoms of MDD (6, 7, 84). As 
such, patients who have undergone a chronic immune challenge express a variety of depressive 
symptoms (7, 85). Now, one of the most pressing issues is to determine how inflammatory 
cytokine signaling is linked to a pathway responsible for depression-like behaviors (3). The 
answer to this question could aid in development of new anti-depressant drugs that would benefit 
a large percentage of the population. This is especially pertinent considering that anti-depressants 
are therapeutically effective in only 15% of patients after accounting for the placebo effect (86). 
  Several reports have identified polymorphisms associated with DO expression, an 
elevated immune response and dysregulation of the hypothalamic-pituitary-adrenal axis. 
Polymorphisms in the Ido1 gene are associated with both treatment efficiency of anti-depressants 
(87) and symptomology of depression (88). A polymorphism in the promotor region of the Ido1 
gene (rs9657182, CC genotype) is a risk factor for patients to develop depression after 
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immunotherapy (88). An additional study (89) found that patients are more likely to develop 
symptoms of depression following immunotherapy if they harbored the “high producer” allele 
(IFN+874, T allele) that is associated with elevated IFN expression (90, 91). This allele is also 
associated with increased DO activity (89, 92), suggesting that this genotype may be a risk factor 
for increased interferon/DO-induced depression (93). There are also functional polymorphisms 
in the GR gene associated with symptoms of depression (94-96). These data provide 
accumulating evidence for convergence of immune (IFN → DO) and stress (HPA 
dysregulation/corticosteroid → GR activation → DO expression) pathways involved in 
depression. The least characterized aspect of this convergence is the interaction between these 
two pathways as regulatory pathways controlling DO expression.  
Extensive research has illustrated mechanisms by which inflammatory challenge induces 
a depression-like phenotype with rodent models. Administration of LPS, pI:C, or infection with 
Mycobacterium bovis evokes peripheral and CNS cytokine expression followed by the 
manifestation of depression-like behaviors such as helplessness/despair (increased immobility 
during tail suspension test, TST) and anhedonia (decreased sucrose preference (32, 33). 
Importantly, development of depressive symptoms is tied to elevated tryptophan metabolism to 
kynurenine via the DOs (38) which are rate limiting for the metabolism of tryptophan to 
kynurenine (Kyn) via the Kynurenine Pathway (12-14, 97). Ido1, Ido2 and Tdo2 mRNA 
expression are induced within the brain and peripheral tissues by LPS and bacterial infection, 
pI:C and viral infection, and systemic and CNS administration of pro-inflammatory cytokines 
(10, 12-14, 98-101). Inflammatory cytokines released during an immune challenge include IFN, 
IFNα, interlukin-1 beta (IL-1ß), IL-6 and tumor necrosis factor alpha (TNF. These cytokines 
are necessary to activate both lymphoid and myeloid cells in the periphery and induce 
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neuroinflammation, but their presence is not sufficient to induce depression-like behaviors. DO 
induction is requisite for depressive-like behaviors as genetic knockout of Ido1 gene 
transcription (Ido1
KO
 mice) inhibits inflammation-dependent depression-like behaviors (11, 14, 
97). Kyn produced by the DOs is not directly responsible for behavioral changes. Kyn is further 
metabolized by non-rate-limiting enzymes: kynureninase (Kynu) + kynurenine 3-
monooxygenase (KMO) leading to quinolinic acid (QuinA) production or by kynurenine 
aminotransferase (Kat2) that generates kynurenine acid (KynA) (46). QuinA and KynA directly 
interact with neurons to interfere with neurotransmitter activity, and they are believed to be the 
end products responsible for the behavioral changes that are initiated and dependent on DO 
expression. KynA acts on neurons to decrease glutamate and acetylcholine signaling, whereas 
QuinA enhances glutamate receptor activation on neurons, suggesting that Kyn metabolites play 
distinct roles in the pathophysiology and etiology of a variety of neurological conditions (47, 48). 
Similar to the effects of cytokines, a recent study has shown that elevated corticosteroids 
increase Ido1 expression in the mouse hippocampus (102). Chronic unpredictable mild stress 
increases both serum corticosterone and Ido1 and leads to depression-like behaviors of rats 
(103). Additionally, swimming stress is well known to elevate blood corticosterone levels in 
mice, and when combined with systemic LPS injection, there is an induction of Ido2 expression 
in the mouse hippocampus (99). These data suggest that inflammatory cytokines and stress 
hormones can act both alone and together to induce Ido1 and Ido2 expression. Although several 
papers indicate elevated Tdo2 expression in the liver following corticosteroid administration 
(104, 105), there are no studies investigating the regulation of Tdo2 within the brain. 
Unfortunately, the DO specificity, inflammatory-mediator specificity and corticosteroid-receptor 
specificity or their interactions have not been defined.  
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Our first attempts to define the interaction between inflammation and stress for the 
regulation of DO within the brain were met with mixed results. Results differed when we used 
qPCR assays that amplified the 5' regions of the DOs versus qPCR assays that amplified 3' 
regions of the DOs. This discrepancy was addressed by purchasing or designing qPCR assays the 
specifically amplified the unique splice variants for each DO (Fig. 2). Since both inflammatory 
stimuli and stress hormones induce depression-like behaviors and DO upregulation, we 
hypothesized that inflammatory stimuli and glucocorticoids interact to regulate DO expression. 
More importantly, we hypothesized that splice variants for the DO exist as a means to 
differentially regulate DO expression dependent on the type of stimuli presented to the brain. We 
found that both Dex and Cort (but not Aldo) attenuate LPS and pI:C-induced pro-inflammatory 
cytokine expression, a typical anti-inflammatory response. Surprisingly, instead of diminishing 
the effect of inflammatory stimuli on Ido expression, corticosteroids upregulated IFN-induced 
Ido1 expression in a transcript dependent manner. The corticosteroids had minimal effects on 
Ido2 expression, but Ido2 was induced by both LPS, pI:C and IFN, whereas Ido1 was only 
induced by IFN. Only one of three Tdo2 transcripts was induced by corticosteroids. These data 
uncover novel pathways that can be manipulated to control DO expression. 
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2.3 Methods 
Mice 
C57BL/6J founders were purchased from Jackson Laboratories. Pups were supplied from 
a breeding colony established and maintained in the University of Illinois’s Institute for Genomic 
Biology animal facility. All animal care and use procedures were conducted in accordance with 
the Guide for the Care and Use of Laboratory Animals (National Research Council) and 
approved by the Institutional Animal Care and Use Committee. 
Reagents 
Hank’s balanced salt solution (HBSS, SH30030.03), heat-inactivated horse serum 
(SH30074.03) and MEM (SH30024.02) were purchased from Hyclone (Logan, UT). D-glucose 
(15023-021) was from Gibco (Carlsbad, CA). Gey’s balanced salt solution (GBSS, G9779), pI:C 
(tested at 10 µg/ml, P0913), Dex (tested at 12.5 µM, D4902), Aldo (tested at 100 nM, A9477), 
Cort (tested at 1 µM, 27840) and LPS (tested at 2 µg/ml, Escherichia coli 0127:B8, L-3129) 
were from Sigma (St. Louis, MO). Recombinant mouse IFN (tested at 1 µg/ml, 315-05) was 
from Peprotech (Minneapolis, MN). Since there are no publications describing the corticosteroid 
responsiveness or corticosteroid x inflammation interactions of OHSCs, we used treatment doses 
to assure that consistent OHSC responses to both types of stimuli were present. 
Organotypic Hippocampal Slice Cultures (OHSCs) 
OHSCs were prepared from 7-10 d old pups as previously described (10). Briefly, mice 
were decapitated and brains were removed, followed by extraction of the hippocampi from both 
brain hemispheres. Transverse slices (350 µm) were prepared with a McIlwain tissue chopper 
(Campden Instruments Ltd, UK) then transferred onto porous (0.4 μm) transparent membrane 
inserts (30 mm in diameter; EMD Millipore) with one slice from each of six different mice per 
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insert. Inserts were placed into six-well culture plates with 1.25 ml of culture medium composed 
of 25 % heat-inactivated horse serum, 25 % Hank’s Balanced Salt Solution (HBSS), 50 % 
Modified Eagle’s Medium (MEM), 1 x penicillin/streptomycin (Pen/Strep), 0.5 % D-glucose and 
15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer pH 7.4). Plates were 
maintained in a humidified incubator (5 % CO2, 95 % atmospheric air) at 37 °C. Medium was 
changed every 2-3 days. On day 7 in culture after slices had recovered from the inflammatory 
response associated with slice preparation (10), OHSCs were rinsed several times and incubated 
for 2 h in serum-free conditions (Dulbecco's MEM, Pen/Strep, HEPES and 150 µg/ml bovine 
serum albumin) before a replacement of the serum-free medium and addition of treatments. Six 
hours following addition of treatments, supernatants and tissues were collected and stored at -80 
°C for further analysis. A six hour treatment duration was chosen based on our finding that the 
maximal cytokine and Ido1 mRNA responses to LPS occurred after this duration (10).  
Reverse transcription and Real-time RT-PCR 
Total RNA from OHSCs was extracted using a commercially available kit as per the 
supplier’s instructions (E.Z.N.A. Total RNA Kit II, Omega Bio-Tek, Norcross, Georgia). RNA 
was reverse transcribed to cDNA using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Grand Island, NY). The cDNA samples were analyzed for steady-state 
mRNA levels (i.e. gene expression) by qPCR using TaqMan universal PCR master mix and the 
Prism 7900 thermocycler (Applied Biosystems, Foster City, CA). Data were analyzed using the 
comparative threshold cycle method (GAPDH expression used to normalize target gene 
expression (13). Changes in target cDNA levels were analyzed by comparing 2
-ΔΔCts
, where Ct is 
the cycle threshold. 
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Figure 2. Gene, transcript and qPCR assay information for murine Ido1, Ido2 and Tdo2. Top: Gene structure (to scale) is 
shown in the shaded areas for each of the 3 DOs with each gene having either 11 or 12 exons. Ido1 and Ido2 are contiguous on 
chromosome 8, separated by only 7,733 bp (red bar). Tdo2 is located on chromosome 3. Each of the 3 genes are transcribed into 
multiple transcripts (exon inclusion for unique transcripts are shown below the gene structure, approximate scale) which encode 
full-length (FL) and variant (v) forms of each protein (protein coding areas shown in yellow within each transcript). Splicing 
patterns were taken from two databases (Ensemble and NCBI, neither of which describe all of the variants) and two manuscripts 
(52, 60) all with unique naming criteria. Thus, simplified names for each transcript are used in the manuscript (shown on the left, 
colored text) and database/manuscript sequence names are provided in black text. Ido2-v3 (4 described in (52)) is not listed in 
either database; a partial sequence of this transcript has been published (thick bar area), but when the transcript was over-
expressed it encodes an active enzyme (52) that lacks 12 amino acids (due to the absence of the first 36 bp of exon 5). Invariant 
exons that are used for all mRNA transcripts within DO are grey; exons that vary in usage or length are colored. Bottom: All 
qPCR assays were purchased from IDT. User-specific (custom) assays were designed using the IDT PrimerQuest® Design Tool. 
It is not possible to design an assay specific to Tdo2-FL as its complete sequence lies within Tdo2-v1 (however data within this 
manuscript indicate distinct differences in expression and regulation of Tdo2-FL and Tdo2-v1). Ido2-v3:4, Tdo2-FL/-v1/-v2 
transcript names and Tdo2 exon 0a and 0b exon designations are shown in the figure to agree with published nomenclature (52). 
Specifics shown for each qPCR assay include location (assay location is also shown in upper panel; ), catalog numbers (if 
predesigned by IDT), primer/probe sequences and confirmed amplicon size. 
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DO transcripts and qPCR Assay Design 
Much of this work was prompted by data generated while investigating the mRNA 
expression of DOs across mouse tissues. Results varied dependent on the qPCR assay location. 
However, the average mouse gene has 3 mRNA isoforms (7 for human) (106), suggesting that a 
single qPCR assay may not detect the true expression level of a gene or intimacies of its 
tissue/cellular distribution and regulation. To determine the relevance of gene splicing to the 
DOs, it is important to outline the multiple transcripts for the three DOs. The gene structures and 
transcripts (2 for Ido1, 4 for Ido2 and 3 for Tdo2) are illustrated as are the qPCR assays used to 
quantify each transcript (Fig. 2 bottom). Correct amplicon size for each qPCR assay was 
confirmed by gel electrophoresis. Proteins transcribed from these transcripts (~ 51 kDa Ido1-FL 
(107, 108), ~ 45 kDa Ido1 (probably FL but possibly v1) (109, 110), ~ 54 kDa Ido2-FL (52, 
108), < 54 kDa Ido2-v3 (52), ~ 46 kDa Tdo2-FL (60), ~ 46 kDa Tdo2-v1 (60) and ~ 44 kDa 
Tdo2-v2 (60)) have been expressed and found to encode enzymatically active proteins. Ido2-v1 
and Ido2-v2 transcripts are predicted to encode variant DO proteins that are distinct from the 
confirmed active Ido2-FL and Ido2-v3 encoded proteins (Fig. 2 top, Ensemble and NCBI 
databases); enzymatic activity of these predicted proteins has not been tested. 
Cytokine Levels 
Media collected from slice cultures were analyzed for TNF and IL-6 levels using BD 
OptEIA™ ELISA kits (BD Biosciences; San Diego, CA) following the manufacturer’s 
instructions. 
Statistics 
All data are presented as mean ± SEM. Gene expression data are means of 3-4 
independent OHSC preparations. Two-way analysis of variance was performed using SigmaPlot 
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13.0 software and a 2 x 6 arrangement of treatments. Post-hoc analysis for multiple comparisons 
was performed only in the presence of a significant interaction, as assessed by Holm-Šídák 
method. Significance was set at p < 0.05 for all comparisons.  
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2.4 Results 
Ido1, Ido2 and Tdo2 transcript expression differ between tissues and across brain regions  
Although gene expression has been published for several of the DO transcripts, a 
quantitative comparison of full length (FL) versus variant (v) transcripts has not been performed 
for the 3 DOs within the brain or across tissue types. Comparing brain regions to lung and liver, 
the Ido1-FL transcript is essentially absent (Ct values > 37) in mouse brain (Fig. 3 top), but it is 
expressed in the mouse liver and abundantly so in the lung. In contrast, Ido1-v1 expression is 
lowest in liver, but is expressed in both the frontal cortex and hippocampus (Ct's ~32) and is 
again highest in the lung. The Ido2-FL transcript is lowest in the mouse brain (Ct's ~ 32), 
expressed in lung, but highest in liver, essentially opposite of the expression pattern for the Ido2-
v1 transcript. Unlike either Ido1 or Ido2, Tdo2 transcripts are lowest in the frontal cortex of the 
mouse brain (Ct's ~34), considerably higher in the hippocampus and lung, but highest in the 
liver. These data indicate that tissues differentially express specific transcripts for each of the 
DOs. Thus quantifying DO expression within different tissue may require the use of different 
assays. These data also suggest that distinct mechanisms must exist to determine which transcript 
will be expressed. More importantly, these data indicate that a single qPCR assay does not reflect 
changes in DO transcript levels. This is illustrated using assays that quantify all transcript 
variants for each DO (-Tot). Total DO mRNA expression does not realistically reflect relative 
expression of any given transcript, which is most obvious for Ido2 where Ido2-v1 is highest in 
the frontal cortex whereas Ido2-FL and Ido2-Tot are highest in the liver. 
Given these major differences across tissues and two brain regions, we analyzed 
additional brain regions for the same DO transcripts. As shown in bottom of Fig. 3, each region 
of the mouse brain has a distinct pattern of DO expression. All brain regions from naïve mice 
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have essentially no Ido1-FL transcript expression (frontal cortex average Ct = 38.9, see the figure 
for the average Ct values of each transcript in the frontal cortex). All 4 brain regions express 
varying levels of the other DO transcripts. The frontal cortex is not particularly abundant for any 
DO transcript, however the hypothalamus and striatum are enriched for Ido1-v1 and Ido2-FL 
expression, whereas the hippocampus and to a much lesser extent the hypothalamus, displays 
enriched Tdo2-FL expression. Tdo2-v1 is similarly expressed across these 4 brain regions. Ido1-
Tot reflects Ido1-v1, because of the absence of Ido1-FL. As such, a qPCR assay for Ido1-v1 or 
Ido1-Tot would not detect the essential absence of Ido1-FL across these brain regions. Ido2-Tot 
reflects Ido2-v1 because of the relatively high expression of the variant compared Ido2-FL. Once 
again, note that assaying brain regions with assays for Ido2-v1 or Ido2-Tot would not detect the 
difference in relative abundance of Ido2-FL. Tdo2-Tot expression reflects Tdo2-FL because of 
the similar expression of the variant across brain regions. Therefore, assaying brain regions with 
Tdo2-FL or Tdo2-Tot assays would not detect the constant expression of Tdo2-v1 across brain 
regions.  
The cause of the distribution differences noted above is unknown, but it is clear that 
results will vary dependent on the design of the qPCR assay. As a first step to understand the 
differential regulation of DO expression, qPCR assays designed to quantify the various DO 
transcripts (Fig. 2 bottom) were used to test for differences in DO regulation in the hippocampus. 
Given that Ido1 and Ido2 have previously been shown to be induced by inflammatory signals, 
whereas Tdo2 is purportedly corticosteroid dependent, we next investigated the individual and 
combined actions of inflammatory mediators and corticosteroids on DO expression using 
OHSCs.  
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Figure 3. Ido1, Ido2 and Tdo2 transcript expression differ between tissues and across brain regions. Top: Two brain 
regions (frontal cortex, FrCor; hippocampus, Hip), lung and liver were collected from naïve mice (n=6). Expression of two 
transcripts for each DO is presented to illustrate tissue and brain region specificity. The sample type with the lowest expression 
was set to 1.0, with other samples showing relative expression levels within transcript (i.e. across row, Ct values for FrCor are 
shown to illustrate relative amplification across transcripts). The tissue with the highest relative expression for each transcript is 
highlighted for emphasis. Total DO expression (Ido1-Tot, Ido2-Tot and Tdo2-Tot) was assessed using assays that span exons 
conserved across all transcripts within each gene. Bottom: Similarly, brain regions were collected to quantify differences in 
expression levels across additional brain regions of naïve mice (n=4). Expression within the frontal cortex was set to 1.0 for all 
transcripts and other regions show expression relative to the FrCor. Ct values for each transcript within the FrCor are shown to 
indicate relative amplification level during the qPCR reaction (Ido1-FL is essentially absent in the naïve mouse brain, samples 
without a calculated Ct value are assigned a value of 40 for presentation). For both data sets, mice (10-12 week old) were 
euthanized under CO2, then perfused with cold saline to minimize blood content within samples prior to tissue or brain region 
excision. Samples were then processed for qPCR analysis as described in the methods section for OHSC samples. 
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Dex and Cort elicit expected anti-inflammatory and negative feedback responses by OSHCs  
We previously characterized the pro-inflammatory responsiveness of OHSCs by 
demonstrating that TNF, IL-6 and iNOS expression is induced by both LPS (10) and IFN 
(111). To confirm responsiveness of our slice cultures to corticosteroids, we first tested for the 
widely accepted anti-inflammatory role of corticosteroids and the ability of corticosteroids to 
elicit a negative feedback loop. The glucocorticoid receptor (GR) agonist dexamethasone (Dex), 
mineralocorticoid receptor (MR) agonist aldosterone (Aldo), or corticosterone (Cort; which 
binds to both receptors with varying affinity; MR > GR) were tested in the presence or absence 
of inflammatory mediators (IFN, LPS and pI:C). There was a significant inflammatory mediator 
main effect on both TNF and IL-6 mRNA gene expression and protein secretion. IFN LPS 
and pI:C induced TNF, IL-6 and RANTES mRNA expression (Fig. 4 A, B and C, respectively, 
p ) as well as TNF and IL-6 protein secretion (insets). Dex significantly (p < 0.001) 
decreased the ability of IFN, LPS and pI:C to induce cytokine/chemokine mRNA (Fig. 4 A, B 
and C) and protein expression (insets). Corticosterone had essentially the same effect as Dex (not 
shown). Aldo did not affect cytokine or chemokine expression or secretion (not shown). 
Interestingly, Dex enhanced the ability of LPS and pI:C to induce iNOS expression although Dex 
was ineffective when added alone (Fig. 4D), indicating that signaling through the GR can 
potentiate some inflammatory responses. 
OHSCs express both the GR (Nr3c1) and MR (Nr3c2). As expected, GR expression was 
decreased by Dex (p < 0.001), a negative feedback response, but was unaffected by 
inflammatory mediators (Fig. 4E). Cort mimicked this effect, whereas Aldo was inactive (not 
shown). MR expression was unaffected by these treatments or their combinations (Fig. 4F). 
These data indicate that GRs are expressed and active as would be necessary for an anti-
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inflammatory effect elicited by Dex or Cort, but not Aldo. The lack of an anti-inflammatory 
effect of Aldo is not due to the absence of the MR expression by OHSCs, but an anti-
inflammatory response was not expected by MR activation. FK506 binding protein 5 (fkbp5; 
FKBP51) and 4 (fkbp4; FKBP52) are considered regulators of corticosteroid receptor activity. 
FKBP51 acts as negative regulator by preventing translocation of corticosteroid receptor 
complexes (CR:R) to the nucleus whereas FKBP52 serves a positive regulator by binding to and 
translocating the CR:R complex to the nucleus to self-regulate their activity primarily via the 
regulation of FKBP51 expression (112). To confirm that this pathway was intact in OHSCs, we 
quantified FKBP51 and FKBP52 expression. Similar to other reports, we found that Dex (Fig. 
4G) increased expression of FKBP51 (p < 0.001). The Dex effect was diminished in the presence 
of LPS and pI:C. Cort, but not Aldo (not shown) mimicked this response. Neither Dex (Fig. 4H), 
Cort (not shown), Aldo (not shown), nor inflammatory mediators affected expression of 
FKBP52. 
Together, the data in Fig. 4 establish that the ability of corticosteroids to block or enhance 
specific inflammatory responses (↓ cytokines, ↓ chemokine and ↑ iNOS). Corticosteroids also 
diminish (GR) or enhance (FKBP51) expression of genes that are part of a negative feedback 
regulation of corticosteroid action. Inflammatory mediators can attenuate corticosteroid action (↓ 
FKBP51). This characterization is necessary to confirm that the OHSC response is similar to 
those reported in both animal systems and other in vitro models are intact. These confirmatory 
data were then used to investigate the interaction between corticosteroids and inflammatory 
mediators on the expression of genes within the Kynurenine Pathway. 
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Figure 4. Within OHSCs, Dex elicits a prototypical anti-inflammatory action and acts to down-regulate its own action. 
OHSCs were treated with 3 inflammatory mediators (IFN, LPS, or pI:C) ± Dex. Gene expression of cytokines (TNF and IL-6), 
a chemokine (Ccl5), inducible nitric oxide synthase 2 (iNOS, Nos2), glucocorticoid receptor (GR; Nr3c1), mineralocorticoid 
receptor (MR; Nr3c2) and FK506 binding protein 5 (fkbp5; FKBP51) and 4 (fkbp4; FKBP52) was quantified as were protein 
levels for TNF and IL-6 in conditioned media (inset). Expression levels are relative to control (no inflammatory mediator and 
no corticosteroid) samples normalized to 1.0. * p < 0.05 for the main effect of an inflammatory mediator, p < 0.05 for the main 
effect of Dex;  p < 0.05 post-hoc analysis for an interaction effect for Dex within inflammatory mediator. 
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Dex, Cort and Aldo interact with IFN to induce Ido1 expression 
In control OHSCs, Ido1-FL was essentially absent (Ct values > 37), but Ido1-v1 was 
detectible (Ct < 34), a finding that closely mimics relative expression found in brains of naïve 
mice (Fig. 3) validating the use of OHSCs as a model to quantify Ido1 expression. As we have 
previously shown (111), IFN induced Ido1-FL expression (Fig. 5A, C, E). IFN also induced 
Ido1-v1 (Fig. 5B, D, F) in OHSCs, although the fold increase was not as large as for Ido1-FL. 
Alone, neither Dex (A, B), Cort (C, D), nor Aldo (E, F) changed Ido1-FL or Ido1-v1 expression. 
Interestingly, there was a significant interaction of Dex with inflammatory mediators on Ido1-FL 
(F(3,22) = 8.1, MSE = 6,120, p < 0.001)and Ido1-v1 expression (F(3,22) = 15.0, MSE = 130.0, p < 
0.001). By post-hoc analysis, Dex significantly accentuated the ability of IFN to induce 
expression of Ido1-FL p  and Ido1-v1 p . Although Cort and Aldo mimicked 
this Dex by IFN interaction, neither reached significance for Ido1-FL. However, there were 
significant interactions between Cort p  and Aldo p  with IFN on Ido1-v1 
expression. Both steroids significantly accentuated the ability of IFN to induce expression of 
Ido1-v1. LPS and pI:C did not induce Ido1-FL or Ido1-v1 expression, nor did they interact with 
Cort, Dex, or Aldo. Collectively, these data suggest a unique regulatory pattern for Ido1 
expression. Unlike cytokines whose expression is diminished by Dex and Cort, Ido1-FL 
transcript expression is accentuated by corticosteroids via GR activation, i.e. by Dex and Cort. 
Unlike iNOS whose expression is increased only by Dex via the GR, Ido1-v1 expression is 
increased by Dex, Cort and Aldo, suggesting mediation by the GR, GR/MR and MR, 
respectively. 
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Figure 5. Two distinct Ido1 transcripts are expressed by hippocampal slice cultures, with IFN being a strong inducer of 
Ido1 expression and synergistic with corticosteroids. OHSCs were treated with IFN, LPS and pI:C ± Dex, Cort or Aldo. 
Expression levels of two Ido1 transcripts are relative to control samples normalized to 1.0. * p < 0.05 for the main effect of an 
inflammatory mediator,  p < 0.05 for the main effect of either Dex, Cort or Aldo;  p < 0.05 post-hoc analysis for an interaction 
effect for Dex, Cort or Aldo within inflammatory mediator. 
 
Inflammatory mediators and Aldo induce Ido2 transcripts  
Ido2-FL was essentially absent (Ct values > 37) in OHSCs and was not inducible by 
inflammatory mediators, corticosteroids, or their combination (not shown). In contrast, Ido2-v1 
(Ct ~ 32), Ido2-v2 (Ct ~ 33) and Ido2-v3 (Ct ~ 33) were all detectable in OHSCs. The lower Ct of 
Ido2-v1 compared to Ido2-FL of OHSCs agrees with the relative Ct levels in the hippocampus of 
naïve mice (Fig. 3) validating the use of OHSCs as a model to quantify Ido2 expression. Ido2-v1 
(Fig. 6A, D, G), Ido2-v2 (Fig. 6B, E, G) and Ido2-v3 (Fig. 6C, G, I) expression was induced by 
IFN (p < 0.001), with the fold induction of Ido2-v1 (~ 12 fold) and Ido2-v3 (~ 10 fold) being 
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greater than that for Ido2-v2 (~ 3 fold). In contrast to Ido1 expression, LPS and pI:C induce 
Ido2-v1 (p < 0.001) and Ido2-v3 (p < 0.001) expression, but like Ido1 they do not increase Ido2-
v2 expression. Interestingly, Dex did not significantly change Ido2 expression, although there 
was a significant interaction between Cort and inflammatory mediators for Ido2-v3 expression 
(F(3,23) = 5.6, MSE = 24.4, p < 0.01). By post-hoc analysis, Cort significantly accentuated the 
induction of Ido2-v3 in the presence of IFN p . Cort did not alter LPS nor pI:C action. 
There was neither a Cort (A, B, C) nor Dex (D, E, F) main effect nor a significant interaction 
between either Cort or Dex and inflammatory mediators for Ido2-v1 and Ido2-v2. However, 
there was a small but significant main stimulatory effect of Aldo on Ido2-v1 expression (Fig. 6G) 
(p < 0.05). Thus, although there was not a significant interaction between Aldo and inflammatory 
mediators, MR activation may enhance Ido2-v1 expression. These data suggest that the 
regulation of Ido2 expression is distinct from Ido1. Ido2 does not appear to be responsive to GR 
activation, although MR activation has a mild stimulatory effect that is highly dependent upon 
the transcript being assessed. Importantly, the 3 Ido2 transcripts detected in OHSCs are 
differentially regulated by IFN, LPS and pI:C. This later finding illustrates again that qPCR 
assay design will affect the response elicited in a treatment-dependent manner. 
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Figure 6. Three distinct Ido2 transcripts are expressed by hippocampal slice cultures, with IFN, LPS, pI:C and Aldo 
inducing expression of specific Ido2 transcripts. OHSCs were treated with IFN, LPS and pI:C ± Dex, Cort or Aldo. 
Expression of Ido2 transcripts are relative to control samples normalized to 1.0. * p < 0.05 for the main effect of an inflammatory 
mediator,  p < 0.05 for the main effect of Dex, Cort or Aldo;  p < 0.05 post-hoc analysis for an interaction effect for Dex, Cort 
or Aldo within inflammatory mediator. 
 
Dex and Cort induce Tdo2-FL expression 
A few studies have suggested that glucocorticoids regulate Tdo2 expression by peripheral 
tissues (104, 105), however, corticosteroid regulation of specific Tdo2 transcripts has not been 
reported. Here we show that all three Tdo2 transcripts are expressed by OHSCs with varied 
amplification results; average Ct's were ~29, ~25 and ~25 for Tdo2-FL/v1, Tdo2-v1 and Tdo2-
v2, respectively. Thus, Tdo2-v1 has a lower Ct value than Tdo2-FL/v1 in both OHSCs and in the 
hippocampus of naïve mice (Fig. 3), again validating the use of OHSCs as a model to quantify 
DO expression. Addition of IFN, LPS and pI:C did not alter the expression of any Tdo2 
transcripts (Fig. 7A-F), but both Dex (Fig. 7A; p < 0.001) and Cort (Fig. 7D; p < 0.05) induced 
Tdo2-FL/v1 expression. As Tdo2-FL/v1 expression is shown to be highest in the hippocampus 
(Fig. 3), a brain region with a high density of both GRs and MRs (113, 114), it is not surprising 
that both Dex and Cort induce Tdo2-FL. Aldo did not alter Tdo2-FL expression (not shown), 
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indicating that the stimulatory effects of Cort and Dex are mediated by the GR. Surprisingly, 
Tdo2-v1 and Tdo2-v2 expression were not regulated by corticosteroids. Since the assay for 
Tdo2-FL also amplifies Tdo2-v1, the latter having a lower Ct and thus possible greater 
expression level, the true inductive power of Cort and Dex on Tdo2-FL expression is diluted by 
the concurrent detection of the non-inducible Tdo2-v1 transcript. This finding confirms that the 
Tdo2-FL sequence is not just a truncated/incomplete version of Tdo2-v1, but that Tdo2-FL is a 
unique transcript under distinct regulatory control compared to its two counterparts. These 
results also indicate that quantifying corticosteroid induction of Tdo2 is only feasible when 
assessing expression of the Tdo2-FL transcript. 
 
Figure 7. Three distinct Tdo2 transcripts are expressed by hippocampal slice cultures with Cort and Dex inducing only 
Tdo2-FL. OHSCs were treated with IFN, LPS and pI:C ± Dex or Cort. Expression levels of Tdo2 are relative to control samples 
normalized to 1.0. p < 0.05 for the main effect of either Dex or Cort. 
 
Changes in the genetic expression of enzymes downstream of DOs along the Kynurenine 
Pathway  
There are several enzymes involved in the metabolism of tryptophan along the 
Kynurenine Pathway. Although the DOs are rate limiting for entry of tryptophan into the 
pathway, downstream enzymes are necessary for the conversion of Kyn to either QuinA or 
KynA. Kat2, Kynu, KMO and Haao are involved in the conversion of Kyn neuroactive 
metabolites (Fig. 8 picture insert). By analyzing the expression pattern of three of these enzymes, 
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we further emphasize the unique transcriptional regulation of the DOs. None of the downstream 
enzymes were inducible by Dex, Cort or Aldo and none showed the positive interaction between 
inflammatory mediators and GR or MR activation. There was an inflammatory main effect on 
KMO and Kynu expression in which both LPS and pI:C significantly induced the expression of 
KMO (Fig. 8A) (p 0.01) while IFN and LPS significantly increased Kynu (Fig. 8B) (p < 
0.05). Dex decreased expression of KMO (p < 0.05) and Kynu (p < 0.001). Haao expression was 
not changed by any of the treatments nor their combination (Fig. 8C). In contrast, LPS and pI:C 
significantly decreased Kat2 expression (p < 0.001), without an effect of Dex (Fig. 8D). The 
actions of Dex on Kynu and KMO expression were mimicked by Cort, but not Aldo (not shown). 
These findings support the hypothesis that corticosteroids regulate expression of KMO and Kynu 
enzymes via the GR. Overall, the stimulatory effect of inflammatory mediators on Kynu and 
KMO expression in parallel with a decrease in Kat2 expression should shift Kyn metabolism 
towards QuinA production (Fig. 8 insert). This effect would be somewhat tempered by the 
inhibitory effect of Dex on Kynu and KMO expression. More importantly, the non-rate limiting 
enzymes are not susceptible to the positive interaction between IFN and corticosteroids to 
induce Ido1 or the induction by Aldo or Dex seen with Ido2 and Tdo2, respectively. 
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Figure 8. Regulation of mRNA expression of enzymes downstream of the DOs in the Kynurenine Pathway in hippocampal 
slice culture. OHSCs were treated with IFN, LPS and pI:C ± Dex. Kynu, KMO, Haao and Kat2 expression was quantified 
relative to control samples normalized to 1.0. * p < 0.05 for the main effect of an inflammatory mediator,  p < 0.05 for the main 
effect of Dex. 
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2.5 Discussion 
Induction of the Kynurenine Pathway by inflammatory stimuli or stress has been 
associated with development of depression-like behaviors (10, 12-14, 97, 100). An 
understanding of the regulation of enzymes within this pathway will aid in discovering the 
mechanism for the etiology of inflammation-induced depression. This is the first study to 1) 
design assays for specific mRNA transcript variants of Ido1, Ido2 and Tdo2, 2) describe tissue 
specificity for each variant and 3) uncover a novel interaction between inflammatory mediators 
and stress hormones to induce specific Ido1, Ido2 and Tdo2 mRNA transcript variants. OHSCs 
were used to model how the hippocampus responds to corticosteroids and inflammatory stimuli. 
We validated the OHSC model by showing that GR, but not MR, activation elicits an anti-
inflammatory response while initiating a negative feedback loop (↓ GR, ↑ FKBP51). Thus, 
OHSCs maintain corticosteroid responses that occur in the intact murine brain. Unexpectedly, 
LPS and pI:C induced iNOS expression was accentuated by Dex. Microglial iNOS expression is 
induced by LPS but attenuated by Dex (115, 116). However, after 6 h (as in the current study), 
Dex did not attenuate the LPS-induced iNOS promoter activity in astrocytes (117). Thus not all 
cells respond with a diminution of iNOS expression. The cell type, or cell-cell interaction within 
OHSCs, that mediates Dex-enhanced iNOS expression is unknown at this time. 
In contrast to the expected anti-inflammatory response, Dex, Cort and Aldo amplified the 
ability of IFN to increase Ido1 expression, establishing that both GR and MR activation are 
involved in the induction of Ido1. Whether corticosteroids synergize with IFN to induce Ido1-
FL or Ido1-v1 expression by a specific cell type(s) is unknown. Additionally, we found that 
OHSC's express 3 Ido2 transcripts. IFN induced expression of all 3 transcripts whereas LPS and 
pI:C increased expression of only 2 transcripts. Aldo and Cort, but not Dex, upregulated 
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expression of specific Ido2 transcripts although these responses were muted compared to that of 
Ido1. Aldo moderately induced expression of Ido2-v1 independent of inflammation, while Cort 
interacted with IFN to accentuate expression of Ido2-v3. These findings suggest a small but 
significant MR-mediated regulation of Ido2. Finally, OHSC's express 3 Tdo2 transcripts; Cort 
and Dex (not Aldo) increase expression of only one Tdo2 transcript, indicating a GR-mediated 
stimulatory response. These important data are essential in further understanding the regulation 
of the Kynurenine Pathway in the brain and detailing the importance of investigating post-
transcriptional regulation of the DO genes.  
Ido1 expression is induced by IFN in human and mouse microglia, macrophages, 
astrocytes (118-122), neurons (123), brain endothelial cells (124) and mouse OHSCs ((53); Fig. 
5). However, although extremely critical to our understanding of DO regulation, none of these 
manuscripts provide enough information to determine basal expression or to identify variations 
in transcript(s) responsiveness to IFN. In the current work and as suggested in the literature, 
Ido1-FL mRNA expression is extremely low to undetectable in the naïve mouse brain (Fig. 3) 
(61, 125), including the hippocampus (126). Although there is essentially no Ido1-FL mRNA in 
the naïve mouse brain, there is Ido1 enzymatic activity (127-129). Enzymatic activity attributed 
to Ido1 in the naïve must derive from the protein product of Ido1-v1. Similarly, we have shown 
that control OHSCs have Ido1 enzymatic activity (10); OHSCs express Ido1-v1 but not Ido1-FL 
(Fig. 4). As such, basal Ido1 activity within OHSCs (like naïve mouse brain) must be mediated 
by the Ido1-v1-encoded protein. Confirmation of this conclusion awaits overexpression of this 
variant and assessment of its activity. Austin (107) over-expressed a ~ 51 kDa Ido1-FL protein, 
whereas Ball (108) and Pallotta (109) over-expressed ~ 45 kDa proteins. Whether the enzymatic 
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activity of the smaller proteins was due to Ido1-FL- or Ido1-v1-derived product or whether the 
two products have similar specific activities was unclear.  
We find Ido1-v1 in all brain regions examined (Fig. 3) with particular enrichment in the 
striatum and hypothalamus. The relevance of this finding relative to animal behavior, especially 
relative to inflammation- and stress-induced depression-like behavior and innate immune 
responses in the CNS, warrants further investigation. To determine the human relevance of DO 
transcript regulation, we have generated assays to measure human Ido1, Ido2, and Tdo2 variant 
transcripts. We detected multiple Ido1, Ido2 and Tdo2 transcripts (unpublished data) in human 
cells. Several Ido1 and Ido2 transcripts were IFN inducible and further induced by 
corticosteroids. This work suggests that the complex regulation of DO transcripts that we have 
identified in the mouse hippocampus is also present in human cells. Relevance of these finding to 
psychiatric diseases warrants further investigation.  
Glucocorticoid response elements (GRE) modulate GR and MR binding to promotors to 
directly affect gene transcription. Using Motif Map, we found no evidence for a GRE within the 
mouse Ido1 or Ido2 genes. This finding suggests that corticosteroid:receptor complexes (C:GR 
or C:MR) are not binding directly to the Ido1 or Ido2 promotor, but are more likely to interact 
with the IFN signaling cascade to accentuate Ido1 and Ido2 expression. IFN activates the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway, and C:GR's can 
enhance JAK/STAT signaling to increase gene transcription independent of GREs (130-134). 
These published mechanisms suggest that GR activation (by Dex or Cort) enhance Ido1-FL, 
Ido1-v1, Ido2-v3 and iNOS expression via JAK/STAT. To date, the C:MR complex has not been 
shown to directly modulate the JAK/STAT pathway although we did find that Aldo interacts 
with IFN to induce Ido1-v1 expression. The mechanism by which Aldo and IFN interact to 
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induce Ido1-v1 or Aldo acts independently to induce Ido2-v1 expression is unclear at this time. 
Independent of the mechanism, our findings are important because they illustrate a multifaceted 
interaction between corticosteroids and IFN to upregulate genes along the Kynurenine Pathway, 
particularly the rate-limiting enzymes Ido1 and Ido2.  
Ido2-FL mRNA has been reported as low to undetectable in the naïve mouse brain (61, 
108). However, in a separate study using a probe that detects all Ido2 transcripts, Ido2 mRNA 
was detected in neurons of the cerebral cortex and cerebellum (125). Using qPCR, we find Ido2-
FL primarily in the mouse striatum and hypothalamus, whereas Ido2-v1 is expressed uniformly 
across at least 4 brain regions (Fig. 3). Only variant Ido2 transcripts were detectable in OHSCs. 
Unlike Ido1, Ido2 transcripts are induced by LPS and pI:C, in addition to IFN Also, Ido2-v1 
expression is increased by Aldo alone. However, similar to Ido1, Ido2-v2 was induced only by 
IFN Thus, it is clear that Ido2 is regulated in a transcript-specific manner by both inflammatory 
mediators and corticosteroids.  
Proteins encoded by Ido2-FL and Ido2-v3 are enzymatically active although the Ido2-FL 
product has higher activity/unit protein than the variant protein encoded by Ido2-v3 (52). This 
result suggests that differential expression of Ido2 transcripts will have profound effects on net 
enzymatic activity. Thus, it is critical to evaluate expression of all transcripts and ultimately the 
enzymatic activity of each protein variant. Clearly an assay such as the one that quantifies all 
three Ido2 transcripts (Ido2-Tot) does not accurately reflect changes in expression of any given 
variant (Fig. 3), nor would it be expected to parallel enzymatic activity.  
The presence of a significant LPS and pI:C effect on Ido2 expression may relate to an 
undiscovered role for Ido2 during bacterial and viral infections within the brain. The induction of 
Ido1 and Ido2 transcripts by IFN within OHSCs mimics the cytokine-mediated response of the 
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brain to a peripheral infection. This induction is critical to development of depression-like 
behaviors (11, 14). However, based upon data in this report, it is quite possible that specific Ido2 
transcripts will be induced by bacterial (e.g. LPS) or viral (e.g. pI:C) infection within the brain. To 
date there are no studies describing behavioral responses associated with the induction of Ido2, due 
to lack of Ido2-specific inhibitors and only the recent development of Ido2KO mice (52). Thus, the 
role of Ido2 in inflammation-dependent psychiatric diseases is unknown. 
Tdo2 mRNA is present throughout the rodent brain (60, 135). Similar to the study by 
Kanai (60), our results suggest that there are unique and unappreciated roles for the various Tdo2 
transcripts within the brain. Tdo2-FL and Tdo2-v1 encode the same mature protein, while Tdo2-
v2 encodes an N-terminal truncated 'variant' protein. Both Tdo2 protein isoforms have similar 
enzymatic activity (60). Since any qPCR assay designed to quantify Tdo2-FL also assays Tdo2-
v1, it is impossible to independently assess Tdo2-FL expression. However, Tdo2-FL is not a 
simple incomplete sequence of Tdo2-v1 but is rather a unique transcript that is controlled by 
specific regulatory mechanisms. As supported by our OHSCs data: expression of only Tdo2-FL 
is induced by Dex and Cort. This inductive response is probably a direct effect of Dex and Cort 
on GR activation as a GRE motif has been predicted within the Tdo2 gene (136, 137). 
There is a significant amount of research suggesting that elevated Ido1 and Ido2 is 
associated depression-like behavior (11, 14) and elevated Tdo2 expression is linked to 
Schizophrenia (138, 139). With very minimal information on the activity of the proteins 
translated from variant DO transcripts, the results presented in this manuscript are only the first 
step of many necessary to define their role in depression or other psychiatric diseases. Although 
it is generally believed that DO enzymatic activity within the brain of naïve and experimental 
mice (127-129) results from the protein product of Ido1-FL, our data suggest that the expression 
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of other DO variants may be responsible for Kyn production within the brain. Ascertaining the 
enzymatic activity of each transcript product is outside the scope of this study, but such 
knowledge would greatly add to the understanding of the functional relevance of the DOs and 
their relevance to psychiatric diseases.  
In conclusion, our data support a role of the Kynurenine Pathway in major depression 
(140) and suggest that inflammatory and corticosteroid pathways converge to induce DO 
expression. This convergence has not been previously tested. Our data show that Ido1, Ido2 and 
Tdo2 are differentially regulated (summarized in Fig. 8E). Ido1 induction by IFNis enhanced 
by GR and MR activation, suggesting that stress hormones interact with IFN to enhance 
kynurenine synthesis within the hippocampus. In contrast, Ido2 transcripts are activated by IFN, 
LPS and pI:C. Thus Ido2 expression is responsive to peripheral immune-cell-derived IFN 
(resident cells in the brain do not produce IFN) and bacterial or viral infections (via LPS or 
dsRNA), but relatively unaffected by stress hormones. Finally, Tdo2 transcripts are either 
unchanged (v1 and v2) or induced by GR activation (Tdo2-FL) indicating a unique stress 
responsiveness. Associating physiological and behavioral consequences to the differential 
regulation of DO transcripts is beyond the scope of this manuscript. However, these data show 
that rate-limiting enzymes for tryptophan metabolism along the Kynurenine Pathway can be 
differentially regulated to allow the brain to specifically respond to various challenges. 
Quantifying the expression of a single DO or a single DO transcript will not accurately reflect 
the true expression of the tryptophan-degrading enzymes. Thus, it is imperative to evaluate the 
expression of each transcript for both animal and in vitro studies. The current study validated 
assays that are needed to achieve this goal. It is also the first work to describe Ido1, Ido2 and 
Tdo2 variant transcripts within the brain.  
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CHAPTER 3:  Immunomodulatory factors galectin-9 and interferon-gamma synergize to induce 
expression of rate-limiting enzymes of the Kynurenine Pathway in the mouse hippocampus
2
 
 
3.1 Abstract  
Elevated levels of circulating pro-inflammatory cytokines are associated with 
symptomology of several psychiatric disorders, notably major depressive disorder. 
Symptomology has been linked to inflammation/cytokine-dependent induction of the Kynurenine 
Pathway. Galectins, like pro-inflammatory cytokines, play a role in neuroinflammation and the 
pathogenesis of several neurological disorders, but without a clearly defined mechanism of 
action. Their involvement in the Kynurenine Pathway has not been investigated. Thus, we 
searched for a link between galectins and the Kynurenine Pathway using in vivo and ex vivo 
models. Mice were administered LPS and pI:C to determine if galectins (Gal's) were upregulated 
in the brain following in vivo inflammatory challenges. We then used organotypic hippocampal 
slice cultures (OHSCs) to determine if Gal's, alone or with inflammatory mediators (interferon-
gamma (IFN), tumor necrosis factor-alpha (TNF), interleukin-1beta (IL-1), polyinosine-
polycytidylic acid (pI:C) and dexamethasone (Dex; synthetic glucocorticoid)), would increase 
expression of indoleamine/tryptophan-2,3-dioxygenases (DOs: Ido1, Ido2 and Tdo2; Kynurenine 
Pathway rate-limiting enzymes). In vivo, hippocampal expression of cytokines (IL-1β, 
TNFand IFN), Gal-3 and Gal-9 along with Ido1 and Ido2 were increased by LPS and pI:C 
(bacterial and viral mimetics). Of the cytokines induced in vivo, only IFN increased expression 
of two Ido1 transcripts (Ido1-FL and Ido1-v1) by OHSCs. Although ineffective alone, Gal-9 
                                                
2
 Adapted from the published version in the Frontiers in Immunology, Molecular Innate Immunity (renumbered 
figures and formatting): Brooks AK, Lawson MA, Rytych JL, Yu KC, Janda TM, Steelman AJ, McCusker RH. 
Immunomodulatory factors galectin-9 and interferon-gamma synergize to induce expression of rate-limiting 
enzymes of the Kynurenine Pathway in the mouse hippocampus. Frontiers in Immunology. 2016 Oct 17; 7: 422. 
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accentuated IFN-induced expression of only Ido1-FL. Similarly, IFNinduced expression of 
several Ido2 transcripts (Ido2-v1, Ido2-v3, Ido2-v4, Ido2-v5 and Ido2-v6). Gal-9 accentuated 
IFN-induced expression of only Ido2-v1. Surprisingly, Gal-9 alone, slightly but significantly, 
induced expression of Tdo2 (Tdo2-v1 and Tdo2-v2, but not Tdo2-FL). These effects were 
specific to Gal-9 as Gal-1 and Gal-3 did not alter DO expression. These results are the first to 
show that brain Gal-9 is increased during LPS- and pI:C-induced neuroinflammation. Increased 
expression of Gal-9 may be critical for neuroinflammation-dependent induction of DO 
expression, either acting alone (Tdo2-v1 and Tdo2-v2) or to enhance IFN activity (Ido1-FL and 
Ido2-v1). Although these novel actions of Gal-9 are described for hippocampus, they have the 
potential to operate as DO-dependent immunomodulatory processes outside the brain. With the 
expanding implications of Kynurenine Pathway activation across multiple immune and 
psychiatric disorders, this synergy provides a new target for therapeutic development. 
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3.2 Introduction  
There is a widely accepted association between activation of the immune system and 
major depression, with a multitude of studies showing that elevated levels of pro-inflammatory 
cytokines are found within the circulation of patients with MDD (141). Furthermore, up to 45% 
of patients receiving immunotherapy (IFN) for hepatitis C or cancer have a greater severity of 
symptoms of MDD (7, 84). Extensive work using rodent models has detailed the induction of 
depression-like behaviors, anhedonia (decreased sucrose preference) and helplessness/despair 
(increased immobility during forced-swim and tail-suspension tests) after administration of LPS, 
pI:C or infection with Mycobacterium bovis (9, 58, 142, 143). These immune activators induce 
neuroinflammation; however the mechanism(s) linking inflammation and depression is widely 
debated. One probable causal factor is altered tryptophan metabolism. 
Elevated tryptophan metabolism to kynurenine (Kyn) via rate-limiting DOs, is correlated 
to the development of depression-like behaviors in rodent models (14) and severity of depression 
behaviors in patients with MDD (7). Expression of all three DO enzymes (Ido1, Ido2 and Tdo2) 
is increased following activation of the immune system. Their expression is increased by LPS 
(mimicking a bacterial infection), pI:C (mimicking a viral infection) and administration of pro-
inflammatory cytokines (10, 12-14, 98-101). In contrast, in the absence of Ido1 (knockout mice), 
inflammation-dependent depression-like behaviors are attenuated (11, 14, 97). Inflammation-
induced behavioral changes are largely attributed to increased Trp metabolism to Kyn followed 
by non-rate limiting Kyn conversion to downstream neuroactive metabolites quinolinic acid 
(QuinA) and kynurenic acid (KynA) (9). QuinA and KynA bind to the N-methyl-D-aspartate and 
7nAChR receptors to either enhance or decrease neurotransmitter signaling, respectively. An 
imbalance of these two metabolites is linked to several neurological diseases (36, 144, 145).  
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Galectins are β-galactoside-binding proteins. Although their mechanism of action is still 
unclear, Gal-1, Gal-3 and Gal-9 are believed to play significant roles in neuropathology and 
neuroinflammation (67). Gal-1 is typically classified as anti-inflammatory and neuroprotective: 
suppressing IFN-induced responses of microglia (146), glutamate neurotoxicity (147) and 
neurodegeneration (146). Gal-1 knockout mice are more susceptible to developing experimental 
autoimmune encephalomyelitis, a mouse model used to mimic MS symptomology. Gal-3 and 
Gal-9 both have context-specific immunomodulatory capabilities (66, 148-151). As examples, 
Gal-3 increases secretion of pro-inflammatory cytokines (150) from microglia and astrocytes, 
while Gal-9 is a potent chemoattractant (152) and up-regulates IFN production (153, 154).  
A galectin - DO connection has not been directly linked to neuropsychiatric disorders, but 
there are several incidences of increased expression of both Gal-9 and Ido1. Increased expression 
of both Ido1 and Gal-9 are associated with MS (70, 71, 78), Grave’s disease, Hashimoto’s 
disease (155, 156) and rheumatoid arthritis (157, 158). Although the pathophysiology of these 
disorders is still unclear, a synergy between Ido1 and Gal-9 may be a crucial uncharacterized 
mechanism involved in the initiation and/or severity of immune disorders. 
Data suggest that Gal-1, Gal-3 and Gal-9 modulate neuroinflammation, however there is 
no evidence directly connecting galectins to the Kynurenine Pathway. Thus, we determined 
whether galectins were increased in the mouse brain following peripheral administration of LPS 
or pI:C. We found that both Gal-3 and Gal-9 (plus DOs) were increased in the mouse 
hippocampus during neuroinflammation. We then decided to investigate whether the elevation in 
Gal-3 and Gal-9 were involved in the concurrent increase in expression of the rate-limiting 
enzymes metabolizing tryptophan to kynurenine (the DOs: Ido1, Ido2 and Tdo2) using 
organotypic hippocampal slice cultures. As we have previously shown (1), IFN induced Ido1 
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and Ido2 expression by OHSCs. Interestingly, Gal-9 was able to directly increase Tdo2 
expression and increased both Ido1 and Ido2 expression in the presence of IFN. These are the 
first findings to link immunomodulatory galectin activity to the Kynurenine Pathway, potentially 
providing a new target for neuroinflammatory therapies. The ability to induce expression of the 
rate-limiting enzymes of the Kynurenine Pathway also defines a mechanism by which Gal-9 can 
mediate symptoms associated with several psychiatric conditions. 
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3.3 Methods 
Mice: C57BL/6J mice were maintained in the University of Illinois’s Institute for 
Genomic Biology animal facility. Procedures and animal care were in accordance with the Guide 
for the Care and Use of Laboratory Animals (National Research Council) and approved by the 
Institutional Animal Care and Use Committee. Young adult mice, used for neuroinflammation 
(intraperitoneal, i.p. LPS or pI:C) experiments, were 12 week old males at time of treatment. 
Saline (control), LPS or pI:C treatments were administered prior to the start of the dark cycle. 
LPS (serotype 0127:B8, Sigma, St. Louis, MO) was administered at 330 μg/kg body weight; this 
dose has been shown to elicit neuroinflammation, elevated Ido1, Ido2 and Tdo2 expression and 
depression-like behaviors (159). pI:C (P0913, Sigma, St. Louis, MO) was administered at 12 
mg/kg body weight. Previous work has shown that pI:C also causes cytokine and Ido1 response 
in the hippocampus and depression-like behaviors (58). Mice were sacrificed 6 h post-treatment. 
Cell culture reagents: Heat-inactivated horse serum (SH30074.03), Hank’s balanced salt 
solution (HBSS, SH30030.03), Eagle's minimal essential medium (MEM, SH30024.02) were 
purchased from Hyclone (Logan, UT). D-glucose (15023-021) was purchased from Gibco 
(Carlsbad, CA). Dex (tested at 1 µM, D4902), pI:C (tested at 10 µg/ml, P0913) and Gey’s 
balanced salt solution (GBSS, G9779) were from Sigma (St. Louis, MO). Recombinant mouse 
IFN (tested at 10 ng/ml, 315-05) was from Peprotech (Minneapolis, MN). Gal-1 (1245), Gal-3 
(1197) and Gal-9 (3535), all tested at 1 µg/ml and TNF (tested at 10 ng/ml, 410-MT) were 
purchased from R&D Systems (Minneapolis, MN). IL-1 (tested at 10 ng/ml, IL014) was 
purchased from Chemicon International (Temecula, CA). 
Organotypic Hippocampal Slice Cultures (OHSCs): OHSCs were prepared from 
hippocampi of C57BL/6J pups, 7-10 days old, as previously described (1). Briefly, hippocampi 
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were cut into 350 µm transverse slices with a McIlwain tissue chopper (Campden Instruments 
Ltd, UK) and positioned onto membrane inserts (PICM03050, EMD Millipore) with six slices 
per insert, each slice from a different animal. Inserts were placed into six-well culture plates with 
1.25 ml of medium (50 % MEM, 25 % horse serum, 1 x penicillin/streptomycin (Pen/Strep), 15 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer, pH 7.4), 25 % Hank’s 
Balanced Salt Solution (HBSS) and 0.5 % D-glucose). Every 2-3 days, medium was changed. On 
the seventh day, OHSCs were rinsed three times with serum-free medium (Dulbecco's MEM, 
Pen/Strep, HEPES and 150 µg/ml bovine serum albumin) and incubated for 2 hours. Slices were 
rinsed again with serum-free medium and treatments added to fresh serum-free medium. OHSCs 
were treated with IFN, TNF, IL-1, pI:C or Dex, with or without Gal-9. To determine if 
effects were specific to Gal-9, independent OHSC preparations were treated with IFN and pI:C 
with or without Gal-1 and Gal-3. Six hours later, tissues and supernatants were collected and 
kept at -80 °C for subsequent analysis. 
Reverse transcription and real-time RT-PCR: RNA was extracted using the E.Z.N.A. 
Total RNA Kit II (Omega Bio-Tek, Norcross, GA) and cDNA was prepared with the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY). The cDNA 
was amplified to quantify steady state gene expression by qPCR using TaqMan Universal PCR 
Master Mix and Prism 7900 thermocycler (Applied Biosystems, Foster City, CA). Using the 
comparative threshold cycle method (GAPDH used to normalize target gene expression), 
differences in cDNA levels were determined by comparing 2-ΔΔCts, Ct = cycle threshold (1). 
DO transcripts and qPCR assay design: Our previous publication describes validated 
qPCR assays to quantify the expression of distinct DO transcripts in mouse tissues and OHSCs. 
Assays for Ido1 (Ido1-FL, Ido1-v1), Ido2 (Ido2-FL, Ido2-v1, Ido2-v6, Ido2-v3) and Tdo2 (Tdo2-
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FL, Tdo2-v1, Tdo2-v2) were described (1). Gene structure for Ido1, Ido2 and Tdo2 is shown in 
Figure 9. Structures for the previously described transcripts are shown as well as the exon-
structure of additional Ido1 (Ido1-v2) and Ido2 variants (Ido2-v2; Ido2-v4 and Ido2-v5) that 
were quantified for the first time for this manuscript. Assay specifics for DO transcript analyses 
are shown in Table 1. Probe-based assays were purchased from IDT with custom assays 
fashioned using the IDT PrimerQuest® Design Tool. Correct amplicon size was confirmed by 
gel electrophoresis. Several transcripts (notably Ido1-FL) are not detectable in all naïve mouse 
brain or control OHSC samples (Ct values ‘undetermined’) thus negating the ability to properly 
calculate relative gene expression: for mathematical analysis a Ct value of 40.0 was assigned 
when this occurred. 
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Statistics: Data are reported as mean ± SEM for 3-4 independent OHSC preparations per 
treatment combination and 6 mice/ treatment group for the adult animal study. SigmaPlot 13.0 
software was used to conduct two-way analysis of variance (2-way ANOVA) using a 2 x 6 
(OHSC) or 2 x 2 (in vivo) arrangement of treatments. In the presence of a significant interaction, 
assessed by Holm-Šídák method, post-hoc analyses for multiple comparisons were performed. 
Comparisons were considered significant at p < 0.05.  
Table 1. Assay specifics for analysis of murine Ido1, Ido2 and Tdo2 steady-state gene expression. 
Transcript Exon Span Assay ID or Custom Name  Primer/Probe Sequence Amplicon (bp) 
Ido1-FL 1-3-4  Mm.PT.42.8645095 Forward TTTGCTCTACCACATCCACTG 117 
   Probe 6-FAMCAGATTTCTZenAGCCACAAGGACCCAGGIABkFQ  
   Reverse GCAGCTTTTCAACTTCTTCTCG  
      
Ido1-v1 2-3  Ido1-v ex 2-3 Forward GACCCCGGACGGTAAAATTAT 138 
   Probe 6-FAMTCGGGCAGCZenTCCACATTACAATTCAIABkFQ  
   Reverse TCTCAATCAGCACAGGCAG  
      
Ido1-v2 2b-3-4-5  Ido1-X2-mouse Set 1  Forward CGGACGGTGGAGCTG 256 
   Probe 6-FAMATTGAGAACZenGGGCAGCTTCGAGAAIABkFQ  
   Reverse CGCAGTAGGGAACAGCAATA  
Ido2-FL 1-2-4  Mm.PT.42.8856312 Forward GGAGATACCACATTTCTGAGGA 114 
   Probe 6-FAMCCAGAGGATZenTTGGAAGGAGAAAGCCATIABkFQ  
   Reverse CGATTAAGTGAGGAAGTCTGAGG  
      
Ido2-v1 3-4  Ido2-v ex 3-4 Forward GGACTTTACATCCCTAACCTCAC 131 
   Probe 6-FAMCCTCAGCTTZenCTCGAACCCTGTAACTGTAIABkFQ  
   Reverse CTGCTCACGGTAACTCTTTAGG  
      
Ido2-v2 3'-4  Ido2-X4 Set 4  Forward AAGCCTGCGGAGCAAAG 88 
         Ido2-X2-mouse Set 1 Probe 6-FAMTGAAGAGATZenGAGCAATGAGCCGGTIABkFQ  
         Ido2-v2-ex3-4 set2 Reverse GAGGCATCTGTCCTGCCT  
      
Ido2-v3 4-5'-6-7  Ido2-v4-Mz Set1  Forward CCCCAAAAGGTATCCAGGAACT 107 
   Probe 6-FAMCTGACCTGGZenTGCTGACAAACTGGAIABkFQ  
   Reverse ACTGATTTCCAACGGTCCTTCT  
      
Ido2-v4 1-4-5  Ido2-X1b-mouse Set 2 Forward CCAAATCCTCTGATGCCTCTC 148 
   Probe 6-FAMTAAAGAGTTZenACCGTGAGCAGCGCCIABkFQ  
   Reverse AAAGGTGCTGCCAAGATCTC  
      
Ido2-v5/v2 3'-5  Ido2-X2-mouse Set 1 Forward AAGCCTGCGGAGCAAAG 244/253 
   Probe 6-FAMTGAAGAGATZenGAGCAATGAGCCGGTIABkFQ  
   Reverse CCAAGTTCCTGGATACCTCAAC  
      
Ido2-v6/v2 3'-4  Ido2-v2-ex3-4 set2  Forward GAGCTGAAGAGATGAGCAATGA 85/85 
   Probe 6-FAMAGGACAGATZenGCCTCTCCTGGACTIABkFQ  
   Reverse ACGGTAACTCTTTAGGAATCTGC  
Tdo2-FL/v1 1-2  Mm.PT.42.9084201.g Forward CCTGAGACACTTCAGTACTATGAG 99/99 
   Probe 6-FAMCCCGTTTGCZenAGGAAACAGTGTAGGAIABkFQ  
   Reverse CTGTCTTCTTCATTGTCCTCCA  
      
Tdo2-v1 0a-0b-1  Tdo2 variant1 exons 0a 0b-1.2 Forward CCAGTACGAAATGAGATCCGG 132 
         Mm.PT.42.9084201.g Probe 6-FAMAGACACAGCZenCAATCAGCACCCAIABkFQ  
   Reverse AGGTTTGCTAGGTCAGGAATG  
      
Tdo2-v2 0a-2  Tdo2 variant2 exons 0a 1.2 Forward GAAATGAGATCCGGGCTAAGAG 78 
   Probe 6-FAMTGGGTGCTGZenATTGGCTGTGTCTIABkFQ  
   Reverse GTGTATCTTTTATGTATCCTGATTGCC  
Probe based qPCR assays were obtained from IDT. The IDT PrimerQuest
®
 Design Tool was used to design 
custom assays. Assay specifics: location of exons spanned, assay ID, primer/probe sequences and amplicon 
size (confirmed by gel electrophoresis) are shown. The transcript Ido2-v2 is detected by three assays: Ido2-X4 
Set 4, Ido2-X2-mouse Set 1, and Ido2-v2-ex3-4 set2. However, the assay Ido2-X4 Set 4 spans an exon 
boundary unique to the Ido2-v2 transcript. Discerning changes in Ido2-v2 expression is possible using this 
assay. In addition, since the assays that assess Ido2-v5/v2 and Ido2-v6/v2 also detect Ido2-v2, changes in Ido2-
v5 and Ido2-v6 can only be estimated based on unique changes in gene expression using either Ido2-X2-mouse 
Set 1 or Ido2-v2-ex3-4 set2 compared to Ido2-X4 Set 4. 
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3.4 Results 
In vivo: neuroinflammation 
 
LPS and pI:C induce DOs, cytokines and galectins in the mouse hippocampus 
  
Ido1 expression: LPS and pI:C were injected intraperitoneally into adult mice to 
determine if, along with the DOs, brain galectin expression was regulated by neuroinflammation. 
Similar to previous studies (58, 99, 159), hippocampal Ido1 expression was increased within 
several hours of a LPS or pI:C challenge. Both LPS and pI:C induced all three Ido1 transcripts: 
Ido1-FL, Ido1-v1 and Ido1-v2 (all p < 0.01, Figure 10A, B, C), with the greatest fold increase 
seen for Ido1-FL followed by Ido1-v2 (both transcripts essentially absent in the hippocampus of 
naïve/control mice), but only a minor increase for the highly expressed Ido1-v1 (see relative basal 
Ct values in the figure legend). 
 
 
Figure 10. In vivo, hippocampal Ido1 expression is increased after LPS and pI:C administration. Mice were administered 
saline (Ctrl), LPS or pI:C and hippocampi collected after 6 hours. Gene expression of three Ido1 transcripts was measured. 
Expression levels are relative to Ctrl samples normalized to 1.0. * p < 0.05 for the effect of LPS or pI:C. Average Ctrl Ct values 
for each transcript: A) Ido1-FL: Ct = 40.0, B) Ido1-v1: Ct = 29.8 and C) Ido1-v2: Ct = 39.7. Ct values indicate that Ido1-FL and 
Ido1-v2 are essentially not expressed in naïve (Ctrl) mouse hippocampi, whereas Ido1-v1 expression is detectable in all samples. 
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Ido2 expression: Several Ido2 transcripts are expressed in the mouse brain. Ido2-v1, 
Ido2-v3 and Ido2-v6 were increased in the hippocampus following LPS treatment (all p < 0.05, 
Figure 11A, C, F), whereas only Ido2-v1 was elevated by pI:C (p < 0.05, Figure 11A). Using 
assays that specifically assess Ido2-FL, Ido2-v2, Ido2-v4 and Ido2-v5 (Table 1), we found that 
their expression was not induced by either LPS or pI:C (Figure 11B, D, E). Ido2-FL was not 
detectable nor induced (not shown). Tdo2 expression: Tdo2-FL expression was not altered by 
LPS or pI:C (Figure 12A), however both Tdo2-v1 and Tdo2-v2 were increased by pI:C (p < 
0.05, Figure 12B, C).  
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Figure 11. Specific Ido2 transcripts expressed in the mouse hippocampus are increased by LPS and pI:C in vivo. Mice 
were administered saline (Ctrl), LPS or pI:C and hippocampi were collected after 6 hours. Expression of six Ido2 gene transcripts 
was measured. Expression levels are relative to Ctrl samples set to 1.0. * p < 0.05 for the effect of LPS or pI:C. Average Ctrl Ct 
values for each transcript: A) Ido2-v1: Ct = 29.2, B) Ido2-v2: Ct = 28.9, C) Ido2-v3: Ct = 28.4, D) Ido2-v4: Ct = 38.5, E) Ido2-
v5/-v2: Ct = 31.6 and F) Ido2-v6/-v2: Ct = 28.3. Ct values indicate that Ido2-FL (non-detectable, not shown) and Ido2-v4 are 
essentially not expressed in naïve (Ctrl) mouse hippocampi. Expression of other Ido2 transcripts are readily detectable in all samples. 
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Figure 12. In vivo, hippocampal Tdo2 expression is increased after pI:C administration. Mice were administered saline 
(Ctrl), LPS or pI:C and hippocampi were collected after 6 hours. Gene expression of three Tdo2 transcripts was measured. 
Expression is relative to Ctrl, normalized to 1.0. * p < 0.05 for the effect of pI:C. Average Ctrl Ct values for each transcript: A) 
Tdo2-FL: Ct = 21.4, B) Tdo2-v1: Ct = 28.7 and C) Tdo2-v2: Ct = 27.7. Ct values indicate that all three Tdo2 transcripts are well-
expressed in the mouse hippocampus.  
 
Cytokines: Illustrating a classical neuroinflammatory response (99, 160), both LPS and 
pI:C increased IFN, TNF and IL-1 expression in the mouse hippocampus (all p < 0.05, 
Figure 13A, B, C). Gal-1 was expressed, but not induced by LPS or pI:C (Figure 13D), while 
Gal-3 expression was doubled by LPS and pI:C (p < 0.05, Figure 13E). Interestingly, Gal-9 
expression was increased ~ 4 fold by LPS and ~10 fold by pI:C (all p < 0.001, Figure 13F).  
In vivo summary: These data illustrate that neuroinflammation increased the expression 
of Gal-3 and Gal-9 along with the expected increase in pro-inflammatory cytokines. Galectin and 
cytokine induction was accompanied by elevated DO expression within the mouse hippocampus, 
but in a DO and transcript specific manner. Thus, we next investigated which (if any) of the 
induced cytokines or galectins directly mediated the changes in hippocampal DO expression, 
using OHSCs.  
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Figure 13. LPS and pI:C increase expression of pro-inflammatory cytokines and galectins in the mouse hippocampus. 
Mice were administered saline (Ctrl), LPS or pI:C and hippocampi were collected after 6 hours. Gene expression of A) IFN, B) 
TNF, C) IL-1, D) Gal-1, E) Gal-3 and F) Gal-9 was measured and expression is shown relative to Ctrl. * p < 0.05 for main 
effect of LPS or pI:C. 
 
Ex vivo: OHSCs 
 
Gal-9 synergized with IFN to induce Ido1-FL expression 
 As shown previously, IFN induced Ido1-FL (1, 10) and Ido1-v1 expression (1) by 
OHSCs (p < 0.001, Figure 14A, B). Gal-9 alone did not induce expression of any Ido1 transcript, 
however Gal-9 significantly interacted with IFN to accentuate IFN-induced Ido1-FL 
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expression (F(5,24) = 8.02, MSE = 1418, p < 0.001, Figure 14A). In contrast, Ido1-v2 was not 
induced by IFN or Gal-9 (Figure 14C), despite being inducible in vivo.  
Based on our in vivo results showing Gal-1 and Gal-3 expression within mouse 
hippocampus, we tested for Gal-9 specificity by treating OHSCs with Gal-1 or Gal-3. 
Surprisingly, considering their immunomodulatory capabilities, Gal-1 and Gal-3 did not alter 
Ido1 expression alone or in the presence of IFN (Figure 14, insets), suggesting that the synergy 
with IFN was Gal-9-specific. An additional degree of specificity is illustrated by the inability of 
TNF, IL-1β, pI:C or Dex to induce any Ido1 transcript or to synergize with galectins. Thus, the 
elevated expression of IFN and Gal-9 associated with neuroinflammation in vivo would be 
expected to act synergistically to enhance Ido1-FL expression. 
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Figure 14. IFN increases expression of two Ido1 transcripts with Gal-9 interacting to accentuate only Ido1-FL ex vivo. 
OHSCs were treated with IFN, TNF, IL-1, pI:C and Dex ± Gal-9. Additional OHSCs (insets) were treated with IFN and pI:C 
± Gal-1 or Gal-3. Gene expression of three Ido1 transcripts was measured and expression levels are relative to Ctrl samples 
normalized to 1.0. * p < 0.05 for the effect of IFN. p < 0.05 for Gal-9 within inflammatory mediator. Average Ctrl Ct values for 
each transcript: A) Ido1-FL: Ct = 40.0, B) Ido1-v1: Ct = 34.9 and C) Ido1-v2: Ct = 40.0. Ct values indicate that only Ido1-v1 is 
expressed in Ctrl slice cultures, paralleling the relative expression pattern of mouse hippocampi (Figure 10). 
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Gal-9 synergized with IFN to induce the expression of Ido2-v1 
 Similar to our previous publication (1), both IFN and pI:C induced expression of Ido2-
v1 and Ido2-v3 (p < 0.001, Figure 15A, C), but only IFN increased expression of Ido2-v6/v2 (p 
< 0.001, Figure 15F). Interestingly, Gal-9 synergized with IFN to accentuate only Ido2-v1 
expression (F(5,24) = 4.02, MSE = 30.0, p < 0.01, Figure 15A). Three additional Ido2 variants 
were expressed by OHSCs. IFN induced Ido2-v4 and Ido2-v5 expression (p < 0.05, Figure 15D, 
E), but not Ido2-v2 (Figure 15B). These data suggests that each Ido2 transcript is differentially 
regulated. In addition, neither TNF, IL-1β nor Dex increased Ido2 expression, alone or with 
Gal-9. Gal-1 and Gal-3 did not affect Ido2 expression (Figure 15, insets). Thus, the elevated 
expression of IFN and Gal-9 associated with neuroinflammation in vivo would be expected to 
act synergistically to enhance Ido2-v1 expression. 
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Figure 15. IFN increases expression of five Ido2 transcripts with Gal-9 interacting to accentuate only Ido2-v1 ex vivo. 
OHSCs were treated with IFN, TNF, IL-1, pI:C and Dex ± Gal-9. Additional OHSCs (insets) were treated with IFN and pI:C 
± Gal-1 or Gal-3. Gene expression of six Ido2 transcripts was measured and expression levels are relative to Ctrl's normalized to 
1.0. * p < 0.05 for the effect of IFN. p < 0.05 effect of Gal-9 within inflammatory mediator. Average Ctrl Ct values for each 
transcript: A) Ido2-v1: Ct = 32.9, B) Ido2-v2: Ct = 30.6, C) Ido2-v3: Ct = 34.4, D) Ido2-v4: Ct = 40.0, E) Ido2-v5/-v2: Ct = 36.1 
and F) Ido2-v6/-v2: Ct = 33.7. Ct values indicate that Ido2-FL (non-detectable, not shown) and Ido2-v4 are not expressed in Ctrl 
slice cultures, similar to the hippocampus of naïve (Ctrl) mice (Figure 11). 
 
Gal-9 induced Tdo2-v1 and Tdo2-v2 
 All three Tdo2 transcripts are well-expressed by OHSCs (Figure 16, Ct's presented in 
figure legend). Neither IFN, TNF, IL-1β nor pI:C affect Tdo2 expression (all 3 transcripts), 
although Dex has a specific inductive action on the Tdo2-FL transcript (p < 0.05, Figure 16A; as 
previously reported (1)). Gal-9 did not affect the expression of Tdo2-FL, but Gal-9 slightly but 
significantly increased expression of both Tdo2-v1 and Tdo2-v2 (p < 0.05, Figure 16B, C). 
Neither Gal-1 nor Gal-3, alone or in combination with inflammatory mediators, affected Tdo2 
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expression (Figure 16 insets). Thus, the elevated expression of Gal-9 associated with 
neuroinflammation in vivo would be expected to enhance Tdo2-v1 and Tdo2-v2 expression 
within the hippocampus; whereas Tdo2-FL is specifically induced by the glucocorticoid receptor 
agonist, Dex. 
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Figure 16. Dex increases Tdo2-FL, whereas Gal-9 increases Tdo2-v1 and Tdo2-v2 expression ex vivo. OHSCs were treated 
with IFN, TNF, IL-1, pI:C and Dex ± Gal-9. Additional OHSCs (insets) were treated with IFN and pI:C ± Gal-1 or Gal-3. 
Gene expression of Tdo2 transcripts was measured and levels are normalized to 1.0 for Ctrl within each transcript. * p < 0.05 for 
the effect of Dex.  p < 0.05 for the main effect of Gal-9. Average Ctrl Ct values for each transcript: A) Tdo2-FL: Ct = 29.1, B) 
Tdo2-v1: Ct = 26.3 and C) Tdo2-v2: Ct = 25.3. Ct values indicate that all three Tdo2 transcripts are well-expressed in mouse 
hippocampal slice cultures, paralleling their expression pattern in the naïve mouse hippocampus (Figure 12).  
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Gal-9 increased TNF and IL-6 expression 
 Previous work had shown that Gal-9 can increase production of pro-inflammatory 
cytokines, such as TNF from microglia (148). To validate this immunomodulatory action, we 
investigated the ability of our treatments, including Gal-9, to induce an inflammatory response 
by OHSCs. Gal-9, IFN and pI:C induced TNF expression (p < 0.05, Figure 17A), while Gal-9, 
pI:C and IL-1 induced IL-6 expression (p < 0.05, Figure 17B). As expected, Dex decreased 
TNF expression, acting in a typical anti-inflammatory (glucocorticoid-like) manner (p < 0.05). 
Only pI:C increased expression of Gal-9 (p < 0.05); this induction was diminished by Gal-9 (p < 
0.05, Figure 17C). Of note, none of the treatments (or combinations) resulted in detectable 
expression of IFN by OHSCs (not shown). Thus, IFN responsible for Ido1 and Ido2 expression 
is not derived from cells resident in the hippocampal parenchyma, while, in contrast, Gal-9 is 
expressed by the brain. 
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Figure 17. Gal-9 increases expression of pro-inflammatory mediators and down-regulates its own expression ex vivo. 
OHSCs were treated with IFN, TNF, IL-1, pI:C and Dex ± Gal-9. Expression of A) TNF, B) IL-6 and C) Gal-9 was 
quantified. Expression for Ctrl cultures was normalized to 1.0. * p < 0.05 for the effects of IFN, pI:C, IL-1 and Dex.  p < 0.05 
for the main effect of Gal-9.  p < 0.05 effect for Gal-9 within inflammatory mediator. IFN expression was not detected in 
OHSCs. 
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3.5 Discussion  
We previously reported an inflammation-by-stress synergy (IFN x glucocorticoid) that 
functions to accentuate expression of Ido1-FL, Ido1-v1 and Ido2-v3 within the mouse 
hippocampus (1). We now report another exciting synergistic interaction between two 
immunomodulatory factors: IFN and Gal-9 that acts to enhance Ido1-FL and Ido2-v1 expression. 
These data indicate that IFN drives Ido1 and Ido2 induction, but secondary factors determine 
which transcripts mediate the synergistic induction of the Ido’s. We also describe assays to quantify 
expression of multiple Ido1 and Ido2 transcripts in vivo (during neuroinflammation) and ex vivo 
(during inflammatory challenges of OHSCs).  
In vivo, LPS or pI:C induced neuroinflammation (i.e. increased cytokine expression) and 
galectin expression, which was accompanied by increased expression of all Ido1 transcripts, but 
only specific Ido2 and Tdo2 transcripts. This is the first report demonstrating that both LPS- and 
pI:C-induced neuroinflammation involved increased Gal-3 and Gal-9 expression: paralleling the 
elevated expression of IFN, TNF and IL-1. Thus, we treated OHSCs with these cytokines ± 
galectins to determine which factors (or combination thereof) were responsible for elevated DO 
expression in vivo. Using OHSCs, we found that Gal-9 acted independently to increase Tdo2-v1 
and Tdo2-v2 expression but Gal-9 only increased expression of Ido1 and Ido2 in the presence of 
IFN. These findings suggest that Gal-9 plays a previously undefined role in the induction of the 
Kynurenine Pathway.  
Ido1: We previously detailed the regulation of two Ido1 transcripts and compared their 
relative expression across multiple areas of the brain. Ido1-v1 was well-expressed (1) in the mouse 
hippocampus and other brain regions, whereas Ido1-FL is low/undetectable across the naïve mouse 
brain (1). Like Ido1-FL, we now show that a third Ido1 transcript, Ido1-v2, is low/undetectable in 
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the mouse hippocampus of naïve mice (Figure 10). Not only is hippocampal basal expression of 
these three Ido1 transcripts different, but the regulation of Ido1 transcripts by inflammatory 
mediators and corticosteroids is unique as well. Expression of both Ido1-FL and Ido1-v2 were 
induced by LPS and pI:C in vivo (current work), but not ex vivo (1), suggesting that in vivo 
hippocampal responses to LPS and pI:C must be mediated by other secondary factors: presumably 
cytokines and other immunomodulatory mediators. Using OHSCs, we found that only IFN was 
able to directly induce Ido1-FL and Ido1-v1 expression (Figure 14, (1)). Since brain/hippocampal 
IFN is inducible by LPS and pI:C, but OHSCs did not express IFN (not shown), non-resident 
cells from the periphery are probably responsible for the elevated IFN expression within the brain 
that occurs in vivo and thus for the increase in Ido1 expression. Indeed, during neuroinflammation, 
IFN + cells infiltrate the brain (161). Hippocampal Ido1-v2 expression is increased by LPS and 
pI:C in vivo, however we have not, as yet, identified the mechanism responsible for this response; 
none of the treatments including IFN increased Ido1-v2 expression by OHSCs.  
In the naïve hippocampus and control OHSCs, only Ido1-v1 is readily detectable, but Ido1-
v1 expression is far less sensitive to pro-inflammatory induction compared to Ido1-FL. These data 
suggest that Ido1-v1 probably has a major role in basal metabolism (supplying Kyn for 
nicotinamide/NAD+ synthesis (162)), whereas the sizeable induction of Ido1-FL by IFN plus 
either Gal-9 (current work) or glucocorticoids (1) is necessary to meet the increased energy/NAD+ 
demand associated with inflammation (163-165) or stress, respectively (Figure 18). Indeed, 
elevated central nervous system NAD+ levels during experimental MS (166) are associated with 
increased Ido1 (167). An unfortunate consequence of Ido1 induction is elevated production and 
release of downstream neuroactive Kyn metabolites (QuinA and KynA) that mediate depression-
like, anxiogenic and adverse cognitive behaviors (168). 
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Figure 18. Proposed model for Kynurenine Pathway activation in the brain. Multiple studies have shown that in vivo 
administration of LPS or pI:C to mice increased peripheral pro-inflammatory cytokines (including IFN, TNF and IL-1). 
These circulating cytokines, as well as immune cells that produce them, can enter the brain, to stimulate brain parenchymal 
production of additional immunomodulatory agents (cytokines and galectins). Gal-9 (produced within the brain or from the 
circulation) and IFN (from the circulation or infiltrating immune cells) synergize to increase expression of DO transcripts in the 
brain. Ex vivo, IFN is added (since brain parenchyma (i.e. OHSCs) does not express this cytokine), Gal-9 is also added to directly 
test its activity (but Gal-9 is expressed by cells resident to the brain). Independent of the source, IFN and Gal-9 increase DO 
expression in a DO- and transcript-specific manner, modeling in vivo responses. DO induction would increase flux down the 
Kynurenine Pathway to serve two purposes: supplying NAD+ for the brain but with consequences (metabolites, Kyn, KynA and 
QuinA, modulate behavior and immune activity). 
 
Ido2: We recently found that several Ido2 transcripts are differentially expressed across the 
mouse brain, and again, inflammatory mediators and corticosteroids differentially regulate Ido2 
transcripts (1). Obviously, post-translational processing of Ido2 (and Ido1) is not a random process 
but is utilized to fine-tune mRNA expression. A switch in post-translational processing of Ido2 was 
first addressed using macrophages and B-cells, wherein both cell types can switch from expression 
of predominantly Ido2-FL to predominantly Ido2-v3 (52). While investigating Ido2 expression in 
the brain, we had first shown that LPS increased hippocampal Ido2 expression in vivo, using an 
assay that simultaneously quantified all Ido2 transcripts (159). In the current work, we refined our 
understanding of central Ido2 expression by quantifying the regulation of its various transcripts. 
During in vivo neuroinflammation, LPS and pI:C increased hippocampal Ido2 expression in a 
transcript-specific manner. Both LPS and pI:C increased Ido2-v1 expression, however only LPS 
increased Ido2-v3 and Ido2-v6/v2. Since LPS and pI:C were administered intraperitoneally, we 
used OHSCs to identify direct versus indirect mechanisms responsible for Ido2 induction.  
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Together with our previous work (1), OHSC expression of Ido2-v1 and Ido2-v3 was 
increased by IFN, LPS and pI:C, while Ido2-v4, Ido2-v5 and Ido2-v6 were increased slightly but 
by only IFN. These data indicate that LPS and pI:C may act directly or via IFN to induce Ido2-
v1 and Ido2-v3 within the hippocampus. In contrast, in vivo induction of Ido2-v4, Ido2-v5 and 
Ido2-v6 are mediated by IFN. Uniquely, Ido2-v2 is highly expressed but unaffected by 
inflammatory mediators and galectins. Overall, in both the mouse hippocampus and OHSCs, Ido2-
v1 and Ido2-v3 are most susceptible to induction by inflammation, whereas the other transcripts 
are either unchanged in vivo or modestly induced ex vivo. These data suggest that Ido2-v1 and 
Ido2-v3 induction was necessary to increase flux down the Kynurenine Pathway (Figure 18) to 
meet the increased energy (NAD+) demand associated with inflammation (163-165). A 
repercussion of their induction may be altered behaviors associated with Kyn production (52) and 
conversion to QuinA or KynA (145). Other Ido2 transcripts are relatively intractable and involved 
in basal metabolism.  
Gal-9: Excitingly, in the presence of IFN, Gal-9 accentuated Ido1-FL and Ido2-v1 
expression by OHSCs; neither Gal-1 nor Gal-3 affected DO expression. This statistical interaction 
suggests that Ido1 and Ido2 are regulated in a transcript-specific manner by additional factors: 
glucocorticoids (1) and Gal-9 (current work). Although IFN initiates Ido1-FL and Ido2-v1 
induction (and indeed IFN action is necessary for neuroinflammation-induced Ido induction (13)), 
full induction in vivo requires synergy with glucocorticoids or Gal-9. As Gal-9 is expressed in 
many cell types within the brain, expression and induction of hippocampal Gal-9 can occur via 
activation of cells resident to the brain. Gal-9 can bind to many cell surface partners including the 
T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) receptor, as well as directly 
associating with several transcription factors (169) within the cell. Further analysis is required to 
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define which of these possible mechanisms are responsible for Gal-9's ability to enhance IFN-
induced DO expression.  
There are multiple autoimmune disorders associated with elevated levels of both Ido1 and 
Gal-9 (70, 78, 155-158). As Ido2 function is associated with the development of severe rheumatoid 
arthritis symptoms (53), Gal-9's ability to enhance Ido2 expression may promote the development 
or severity of symptoms of rheumatoid arthritis or other autoimmune conditions. Thus, further 
characterization of the synergy between IFN and Gal-9 during the induction of Ido1 and Ido2 is 
important to our understanding the pathophysiology of autoimmune disorders such as MS, 
Hashimoto’s disease, or rheumatoid arthritis. Similarly, Gal-9 is an important regulator of the 
immune system, promoting the differentiation of T regulatory cells (170) and modulating viral 
pathogenesis (171). Ido1 plays a similar role in T cell differentiation (172) and also modulates viral 
pathogenesis (173). These findings open that possibility that one of the mechanisms by which Gal-
9 controls T cell differentiation and viral pathogenesis is its ability to direct DO expression. These 
links warrant further investigation. 
Tdo2: Three Tdo2 transcripts are expressed in the mouse brain, only Tdo2-FL is enriched 
in hippocampus (1, 60). Similar to Ido1 and Ido2, this specific enrichment implies a distinct 
regulatory mechanism for transcript expression. Although Tdo2-v1 and Tdo2-v2 expression was 
increased in the hippocampus post-pI:C administration to mice, treatment of OHSCs with pI:C, 
pro-inflammatory cytokines or LPS (1) did not increase Tdo2 expression. Thus, another factor(s) 
must mediate increased Tdo2 expression in vivo. Using, OHSCs, Tdo2-v1 and Tdo2-v2 expression 
was increased by Gal-9. Since, pI:C was a more potent inducer of hippocampal Gal-9 compared to 
LPS in vivo, the ability of pI:C administration to increase Tdo2-v1 and Tdo2-v2 expression may be 
mediated by central Gal-9 induction. In contrast to Tdo2-v1 and Tdo2-v2, Tdo2-FL expression was 
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increased by glucocorticoids (Dex and corticosterone) in OHSCs (Figure 16; (1)), but not 
cytokines or Gal-9. Thus, like the Ido's, Tdo2 evolved to permit differential transcript expression in 
a stress- and inflammation-specific manner within the brain. Tdo2-FL expression is dependent on 
glucocorticoid activity; whereas, Tdo2-v1 and Tdo2-v2 are responsive to Gal-9. These data suggest 
that different promotors used for Tdo2 induction (174) are necessary to meet the increased 
metabolic (NAD+) demand (Figure 18) associated with stress (Tdo2-FL) and neuroinflammation 
(Tdo2-v1 and Tdo2-v2), as previously suggested (163-165). A repercussion of aberrant Tdo2 
expression may be altered behavior such as those associated with schizophrenia (138, 139) and 
anxiety (54, 55).  
In conclusion: This is the first manuscript to link Gal-9 to the Kynurenine Pathway. 
Following LPS and pI:C administration, IFN and Gal-9 expression are induced within the mouse 
hippocampus, as are Ido1 and Ido2. Using OHSCs, we clearly show that these two inflammatory 
modulators act in synergy to increase Ido1 and Ido2 expression. This ex vivo synergism 
presumably has a role during in vivo induction of Ido1 and Ido2 (Figure 18). Since changes in Gal-
9, IFN and Ido1 expression have been independently linked to central diseases such as depression 
and MS (7, 70, 78, 175), the ability of Gal-9 to accentuate DO expression during 
neuroinflammation may play a significant role in these and other psychiatric conditions and should 
be further studied as a putative therapeutic target. Finally, the action of Gal-9 is highly specific to 
the induction of distinct Ido1, Ido2 and Tdo2 transcripts, suggesting complex post-translational 
control over DO expression. Our understanding of this process is in its infancy. Additional work is 
required to clarify the relevance of DO expression to psychiatric illness, autoimmune disorders and 
neurological disease.  
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CHAPTER 4: Desipramine decreases expression of human and murine indoleamine-2,3-
dioxygenases
3
 
 
4.1 Abstract 
Abundant evidence connects depression symptomology with immune system activation, 
stress and subsequently elevated levels of kynurenine. Anti-depressants, such as the tricyclic 
norepinephrine/serotonin reuptake inhibitor desipramine (Desip), were developed under the 
premise that increasing extracellular neurotransmitter level was the sole mechanism by which 
they alleviate depressive symptomologies. However, evidence suggests that anti-depressants 
have additional actions that contribute to their therapeutic potential. The Kynurenine Pathway 
produces tryptophan metabolites that modulate neurotransmitter activity. This recognition 
identified another putative pathway for anti-depressant targeting. Considering a recognized role 
of the Kynurenine Pathway in depression, we investigated the potential for Desip to alter 
expression of rate-limiting enzymes of this pathway: indoleamine-2,3-dioxygenases (Ido1 and 
Ido2). Mice were administered lipopolysaccharide (LPS) or synthetic glucocorticoid 
dexamethasone (Dex) with Desip to determine if Desip alters indoleamine-dioxygenase (DO) 
expression in vivo following a modeled immune and stress response. This work was followed by 
treating murine and human peripheral blood mononuclear cells (PBMCs) with interferon-gamma 
(IFN and Desip. In vivo: Desip blocked LPS-induced Ido1 expression in hippocampi, 
astrocytes, microglia and PBMCs and Ido2 expression by PBMCs. Ex vivo: Desip decreased 
IFN-induced Ido1 and Ido2 expression in murine PBMCs. This effect was directly translatable 
to the human system as Desip decreased IDO1 and IDO2 expression by human PBMCs. These 
                                                
3 Adapted from the published version in Brain, Behavior, and Immunity (renumbered figures and formatting): 
Brooks AK, Janda TM, Lawson MA, Rytych JL, Smith RA, Ocampo-Solis C, McCusker RH, 2017. Desipramine 
decreases expression of human and murine indoleamine-2,3-dioxygenases. Brain Behav Immun 62, 219-229. 
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data demonstrate for the first time that an anti-depressant alters expression of Ido1 and Ido2, 
identifying a possible new mechanism behind anti-depressant activity. Furthermore, we propose 
the assessment of PBMCs for anti-depressant responsiveness using IDO expression as a 
biomarker.   
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4.2 Introduction 
Currently, over 350 million people world-wide suffer from depression, with about 1 in 20 
people reporting a depressive episode over the last year (176). Even worse, depression is 
predicted to become the leading cause of disease burden world-wide by the year 2030 (177). The 
US population taking anti-depressants has doubled over the past 12 years further highlighting the 
extent of this problem (81). Considering the poor efficacy of anti-depressants for patients 
suffering from Major Depressive Disorders (MDD) (86, 178, 179), identifying additional targets 
for the creation of more-effective therapeutics is of utmost importance.  
A subset of individuals with major depressive disorder present with evidence of an 
activated immune system (increased inflammatory biomarkers) and another subset have 
increased peripheral tryptophan metabolism to kynurenine (Kyn) (141, 180). In patients with 
chronic elevation of inflammatory markers, anti-inflammatory drugs have potential anti-
depressant efficacy (181). Thus, patients with elevated Kyn production should benefit from 
therapeutics that modulate the Kynurenine Pathway. Three rate-limiting dioxygenase enzymes 
(DOs: indoleamine-dioxygenases Ido1 and Ido2, plus tryptophan-2,3-dioxygenase (Tdo2)) 
metabolize tryptophan into N-formyl-kynurenine that is then metabolized into Kyn. In human 
studies, up to 45% of patients with hepatitis C or cancer have a greater severity of depression 
symptoms following immunotherapy with IFN(6, 7, 84) with severity of depression symptoms 
associated with elevated Kyn production , while lipopolysaccharide (LPS) administration to 
subjects induced inflammation and a depression phenotype (182). These studies reveal that 
elevated inflammatory markers are linked to MDD and provide direct evidence that 
inflammation and the Kynurenine Pathway are linked to depressive symptomology (183-185). 
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Activation of the Kynurenine Pathway is associated with induction of inflammation-
induced depression (141, 180). Expression and regulation of the DOs indicate that enhanced DO 
activity and elevated DO expression are correlated with depression symptomology in both 
human and rodent models (1, 7, 13). In preclinical studies, neuroinflammation induced by LPS 
administration, polyinosinic:polycytidylic acid (pI:C) treatment, peritoneal infection with 
Mycobacterium bovis or acute/chronic stress culminate in depression-like behaviors such as 
anhedonia and helplessness/despair (9, 12, 58, 142, 143, 186, 187). Such pre-clinical models of 
depression are associated with increased DO expression and/or DO activity, primarily attributed 
to Ido1 as diminishing DO activity by the administration of Ido1 inhibitors or using Ido1 
knockout (KO) mice results in decreased inflammation- and stress-induced depression-like 
behaviors (11, 14, 97, 187). Peripheral immune challenges, largely via IFNinduce Ido1 and 
Ido2 (1, 13, 99, 188); whereas, stress hormones induce Tdo2 (1) in rodent models. Our recent 
work suggests that stress-inducible factors, glucocorticoids, synergize with IFN to further 
induce the DOs (1, 188). Thus, the induction of the Kynurenine Pathway following inflammatory 
and stress-induced stimulation is intimately associated with depression (7, 9, 13, 58, 142, 143). 
Both Ido1 and Ido2 genes are transcribed into multiple transcript variants, and it is 
possible to distinguish expression of DO transcripts by amplifying regions unique to each 
transcript. As such, the Ido1- full length (FL) transcript (comprised of exons 
1,3,4,5,6,7,8,9,10,11) is poorly expressed in the naïve mouse brain, but is highly inducible by 
inflammation and stress. In contrast, the Ido1-variant 1 (v1) transcript (comprised of exons 
2,3,4,5,6,7,8,9,10,11) is well-expressed in the brain, but far less sensitive to inflammatory stimuli 
(1). This profile suggests the use of alternate enhancer/promoters to control Ido1 expression in a 
transcript-dependent manner. Similarly, Ido2-FL (comprised of exons 1,2,4,5,6,7,8,9,10,11) is 
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poorly expressed and poorly induced by inflammatory mediators or stress in the mouse brain (1). 
Ido2-v1 (comprised of exons 3,4,5,6,7,8,9,10,11) and Ido2-v3 (exon structure unknown) are well 
expressed within the brain and are increased following inflammatory stimuli (188). Similar to 
Ido1, differential relative expression and regulation suggest the use of distinct enhancer/promoter 
sequences to control Ido2 expression(189). Desipramine (Desip; a tricyclic 
serotonin/norepinephrine reuptake inhibitor) is a commonly prescribed anti-depressant. In 
preclinical studies, Desip or its precursor imipramine decreased depression-like behavior of LPS-
treated (65, 100, 190-194) and BCG-infected mice (195, 196). Many such studies attributed the 
induction of depression-like behaviors to Ido1, but no data were provided to determine if Desip 
altered DO expression as a mechanism associated with diminished depression-like behaviors. As 
previous work has shown that Desip or its precursor imipramine can decrease LPS-induced 
depression-like activity (65, 100, 190-194), we investigated the relationship between 
inflammation, Desip and DO expression.  
We confirmed that LPS induces Ido1 expression in vivo in the brain and periphery. 
Interestingly, Ido1 induction was blocked by Desip in the circulation (murine PBMCs, PBMC
-T
s, 
T cells and human PBMCs) and the brain (murine hippocampi, microglia and astrocytes). Using 
organotypic hippocampal slice cultures (OHSCs), we found that IFN-induced Ido1 and Ido2 
expression was blocked by Desip, and furthermore, that our previously described synergy 
between IFN and either Dex (1) or galectin-9 (188) to accentuate specific Ido1 and Ido2 
transcripts were blocked by Desip. Here we provide the first evidence that an anti-depressant 
drug Desip decreases Ido expression in both human and murine samples. This finding identifies a 
putative new mechanism that may be exploited to enhance anti-depressant activity.  
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4.3 Methods 
Mice and in vivo reagents 
C57BL/6J mice were bred in-house. All procedures were in accordance with the Guide 
for the Care and Use of Laboratory Animals (NRC), approved by the Institutional Animal Care 
and Use Committee. Twelve-week-old male C57BL/6J mice were used for intraperitoneal 
injections. Saline or Desip (20mg/kg body weight, D3900, Sigma) were administered 30min 
before saline, LPS (lipopolysaccharide, 330μg/kg, serotype 0127:B8, Sigma) or Dex 
(2,500μg/kg, 11695-4013-1, Henry Shein, Dublin, OH). Treatments were administered prior to 
initiation of the dark cycle and mice were sacrificed 6h post-treatment. This Desip dosage 
blocked LPS-induced depression-like behaviors (100). 
Reagents for ex vivo studies 
Recombinant mouse IFN (tested at 10ng/ml, 315-05) and human IFN (tested at 
10ng/ml, 300-02) were from Peprotech (Minneapolis, MN). Murine Gal-9 (1µg/ml, 3535) was 
from R&D Systems (Minneapolis, MN). Dex (1µM, D4902) was from Sigma. Desip was tested 
at 100µM. 
Microglia and Astrocytes 
Cells were isolated using the gentleMACS system (Miltenyi, San Diego, CA), as 
previously described (197, 198). Briefly, perfused brains were digested with Neural Tissue 
Dissociation reagents. The resulting cell suspension was passed through a 40µm mesh to remove 
debris. After centrifugation, cells were re-suspended in 30% low-endotoxin Percoll Plus (GE 
Healthcare) and centrifuged to remove myelin. Cells were re-suspended in PBS plus 2mM 
EDTA and 0.5% BSA and incubated with microbeads labeled with either anti-CD11b (microglia 
enrichment) or anti-ACSA-2 (astrocytes enrichment). Target cells were separated from non-
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antigenic cells in a magnetic field. Cells were treated for 6h in serum-free medium (Dulbecco's 
MEM, 1x penicillin/streptomycin, 15mM HEPES pH 7.4, 150µg/ml BSA) then stored at -80°C 
for later extraction. Microglia enrichment was previously confirmed by flow cytometry (199) 
and here with IL-1β expression which was 24.0-fold higher in microglia versus astrocytes. We 
have confirmed cells isolated using Miltenyi CD11b
+
 microbeads as CD11b
+
, CD45
low
, and 
Ly6C
−
, considered predominantly microglia, and IL-1β staining as a positive marker for 
activated microglia (198). Astrocyte enrichment was confirmed by Eaat1 expression which was 
31.0-fold higher in astrocytes versus microglia. Multiple studies have described using magnetic 
beads (ACSA-2) to separate a relatively “pure” population of astrocytes from the brain (200-
202), and have confirmed that this population of cells express astrocytic mRNA and do not 
express markers/mRNA/protein specific to other population of cells in the brain (200).  
Murine PBMCs  
Cells were isolated from heparinized blood using Ficoll-Paque PLUS (GE Healthcare) 
according to the manufacturer’s protocol. Briefly, blood was layered above Ficoll-Paque PLUS 
and centrifuged. The mononuclear cell layer (PBMCs) was centrifuged (200xg) twice to remove 
platelets. If PBMCs were from mice treated in vivo, RNA was immediately extracted. If PBMCs 
from naïve mice were to be treated ex vivo, they were separated into CD90
+
 T cells and CD90
-
 
PBMC
-T
s. T cell enrichment: PBMCs were incubated with anti-CD90.2 microbeads (Miltenyi). 
Target cells were separated in a magnetic field with positive (retained-eluted T cells) and 
negative (fall-through PBMC
-T
s) fractions collected. Cd3d expression (T cell marker (203)) was 
~700-fold higher in T cells than PBMC
-T
s; indicating efficient T cell enrichment and removal 
from the PBMC
-T
 fraction. Cells were rested for 1.5h, treated for 6h in serum-free medium then 
stored at -80°C for later extraction. 
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Human PBMCs 
 Cells (purified, characterized PBMCs) from healthy subjects (a 21 year old male and 21 
year old female) were purchased from Precision For Medicine (Fredrick, MD). Cells were 
thawed, centrifuged to remove DMSO, then rested for 2h in serum-free medium. Cells were then 
treated for 6h and stored at -80°C until RNA extraction. 
OHSCs 
C57BL/6J pups were used to generate OHSCs as previously described (1, 188). 
Hippocampi were sliced and placed onto membrane inserts in 6-well plates containing medium 
(50% Eagle's MEM, 25% HBSS, 25% heat-inactivated horse serum, penicillin/streptomycin, 
HEPES, 0.5% D-glucose). On day 7, media was replaced with serum-free medium. OHSCs were 
treated for 6h, then stored at -80°C for later extraction. 
RT-qPCR 
E.Z.N.A. Total RNA Kit II (Omega Bio-Tek, Norcross, Georgia) was used to extract 
RNA. RNA was reverse transcribed to cDNA (High Capacity cDNA Reverse Transcription Kit, 
Applied Biosystems, Foster City, CA), and qPCR was performed using TaqMan universal PCR 
master mix (Applied Biosystems). Gene expression was normalized to GAPDH. Relative 
expression was calculated by comparing 2
-ΔΔCts
, Ct=cycle threshold (1, 188). Previous 
publications (1, 188) describe probe-based assays to measure DO transcripts. Herein, we focused 
on 4 transcripts to quantify Ido1 (Ido1-FL, Ido1-v1) and Ido2 (Ido2-v1, Ido2-v3). 
Plasma IFN 
Blood was collected into heparinized syringes 6h post-treatment, and plasma analyzed for 
IFN (ELISA, BD Biosciences; San Diego, CA) following manufacturer’s instructions. 
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Statistics 
Data are mean±SEM of 6 mice per treatment combination (in vivo experiments) and 3-4 
independent PBMC
-T
, T cell and OHSC preparations. Analysis of variance was conducted with 
SigmaPlot 13.0. Post-hoc analyses (Holm-Šídák) for comparisons across treatment groups were 
performed only with a significant interaction. Significant effects required p<0.05.   
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4.4 Results 
Ido1-FL 
 In vivo, Ido1-FL mRNA expression in mouse brain is strikingly induced by LPS (1, 61, 
125) (but not Dex, data not shown). We found elevated Ido1-FL expression in hippocampus 
(Figure 19A), astrocytes (Figure 19B) and microglia (Figure 19C) from LPS-treated mice, 
compared to controls. Interestingly, Ido1-FL was also induced in PBMCs (Figure 91D). Most 
important, LPS-induced Ido1-FL expression was blocked by Desip in hippocampus, astrocytes 
and PBMCs (with a similar non-significant trend in microglia).  
Ex vivo, IFN is accepted as a major mediator of LPS-induced Ido1 expression. To test if 
Desip was directly blocking IFN activity, samples were treated ex vivo. When PBMCs-T, T cells 
(Figure 19E and 19F) and OHSCs (Figure 19G and 19H) were examined, Ido1-FL expression 
was increased by IFN. We also confirmed the ability of Dex (Figure 19G) and Gal-9 (Figure 
19H) to enhance IFN-induced Ido1-FL (1). Excitingly, Desip decreased IFN-induced Ido1-FL 
in PBMCs
-T
 and T cells. Desip also diminished IFN IFN+Dex or IFNGal-9 induced Ido1-FL 
expression by OHSCs.  
Combined, the in vivo and ex vivo data suggest that the induction and suppression of Ido1-
FL in brain and OHSCs is mediated by astrocytes and microglia. These responses are mimicked by 
PBMCs. 
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Figure 19. Desip decreased Ido1-FL expression. After i.p. treatment of mice with either LPS or Dex (in vivo, A-D) or 
cells/brain tissue with IFN (ex vivo, E-H) with and without Desip, expression of Ido1-FL was quantified in A) Hippocampi, B) 
Astrocytes (ACSA-2+ enriched cells), C) Microglia (CD11b+ enriched cells), D) PBMCs, E) PBMC-T, F) T cells (CD90+ 
enriched cells), G) OHSCs ± Dex and H) OHSC ± Gal-9. * p ≤ 0.05 for Ido1-FL induction by LPS or IFN;  p ≤ 0.05 for the 
inhibitory effect of Desip within LPS or IFN;  p ≤ 0.05 for the ability of Dex or Gal-9 to synergistically enhance IFN-
stimulated gene expression. 
 
Ido1-v1 
 In vivo, Ido1-v1 is well expressed in naïve mouse brain but only mildly (~2-fold) 
increased by LPS (188). Ido1-v1 expression was doubled in hippocampus by LPS (Figure 20A), 
but unaffected by Dex (not shown). Changes in Ido1-v1 are cell-type specific as LPS and Dex 
increased Ido1-v1 in astrocytes (Figure 20B) but not microglia (Figure 20C) or PBMCs (Figure 
20D). Desip tended to depress basal PBMC Ido1-v1 expression (p=0.052, Figure 20D). Unlike 
Ido1-FL, Ido1-v1 expression in vivo was relatively insensitive to Desip.  
Ex vivo, IFN treatment did not significantly induce Ido1-v1 in PBMC-T or T cells 
(Figure 20E and 20F), however Desip decreased basal Ido1-v1 expression in both cell 
populations. In OHSCs, IFN-induced Ido1-v1 (Figure 20G and 20H) was accentuated by Dex 
(Figure 20G). As reported previously (1), Gal-9 did not alter Ido1-v1 (Figure 20H). In all cases, 
IFN-dependent Ido1-v1 expression by OHSCs was decreased by Desip. 
P a g e  | 81 
 
 
Combined, in vivo and ex vivo data suggest that the induction and suppression of Ido1-v1 
in OHSCs is NOT driven by astrocytes and microglia. PBMCs are unique in that Desip inhibits 
basal Ido1-v1 expression. 
 
Figure 20. Attenuation of Ido1-v1 expression by Desip. After treatment of mice i.p. with either LPS or Dex (in vivo, A-D) or 
cells/tissue with IFN (ex vivo, E-H) with and without Desip, expression of Ido1-v1 was quantified in A) Hippocampi, B) 
Astrocytes (ACSA-2+ enriched cells), C) Microglia (CD11b+ enriched cells), D) PBMCs, E) PBMC-T, F) T cells (CD90+ 
enriched cells), G) OHSCs ± Dex and H) OHSC ± Gal-9. * p ≤ 0.05 for Ido1-v1 induction by LPS, Dex or IFN;  p ≤ 0.05 for 
the inhibitory effect of Desip within LPS or IFN;  p ≤ 0.05 for the ability of Dex or Gal-9 to synergistically enhance IFN-
stimulated gene expression; p ≤ 0.05 main effect of Desip. 
 
Ido2-v1 
 In vivo, Ido2-FL is undetectable and not inducible in hippocampus (1, 188) and OHSCs 
(1). Thus, we quantified other well-expressed transcripts: Ido2-v1 and Ido2-v3. LPS (and Dex, 
not shown) did not increase Ido2-v1 expression in hippocampus (Figure 21A), however Ido2-v1 
induction was seen in astrocytes (Figure 21B), microglia (Figure 21C) and PBMCs (Figure 21D). 
Desip did not affect astrocyte Ido2-v1. Desip accentuated LPS-induced Ido2-v1 in microglia but 
attenuated induction in PBMCs. Thus, hippocampal Ido2-v1 expression did not mimic changes 
seen in either astrocytes or microglia, suggesting that the induction seen in these cell types may 
be offset by other cell populations. 
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 Ex vivo, Ido2-v1 expression was numerically higher in PBMC-T (p=0.08) and 
significantly higher in T cells treated with IFN. Independent of this, Desip significantly 
decreased Ido2-v1 in both cell populations (Figure 21E and 21F). IFN also increased Ido2-v1 
expression in OHSCs, an effect unaltered by Dex (Figure 21G) but accentuated by Gal-9 (Figure 
21H). The induction of Ido2-v1 by Gal-9 was blocked by Desip to levels seen with IFN alone. 
Combined the in vivo and ex vivo data suggest that induction and suppression of Ido2-v1 is 
cell-type specific. For the first time, Desip induced a DO transcript (microglial Ido2-v1), but in 
other cells Desip was either inactive (astrocytes or IFNDex OHSCs) or inhibitory (PBMC and 
IFN+Gal-9 OHSCs).  
 
Figure 21. Attenuation of Ido2-v1 expression by Desip. After treatment of mice i.p. with either LPS or Dex (in vivo, A-D) or 
cells/tissue with IFN (ex vivo, E-H) with and without Desip, expression of Ido2-v1 was quantified in A) Hippocampi, B) 
Astrocytes (ACSA-2+ cells), C) Microglia (CD11b+ enriched cells), D) PBMCs, E) PBMC-T, F) T enriched cells (CD90+ 
enriched cells), G) OHSCs ± Dex and H) OHSC ± Gal-9. * p ≤ 0.05 for Ido2-v1 induction by LPS or IFN;  p ≤ 0.05 for the 
effect of Desip within LPS or IFN;  p ≤ 0.05 for the ability of Dex or Gal-9 to synergistically enhance IFN-stimulated gene 
expression. 
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Ido2-v3 
In vivo, LPS (and Dex, not shown) did not increase Ido2-v3 expression in hippocampi 
(Figure 22A), however, Ido2-v3 was increased by Dex in astrocytes (Figure 22B) and by LPS in 
both microglia (Figure 22C) and PBMCs (Figure 22D), similar to Ido2-v1 regulation. 
Unexpectedly, Desip increased Ido2-v3 expression slightly in astrocytes and more so in LPS-
treated microglia. The induction seen in astrocytes and microglia was not evident in 
hippocampus, as these cells are not the major source of this transcript. Thus, the small change in 
astrocytes and even the 20-fold increase in microglia represent a small portion of total brain 
Ido2-v3. Ido2-v3 expression by PBMCs was decreased by Desip, independent of LPS or Dex.  
Ex vivo, although unchanged by IFN, the inhibitory effect of Desip on PBMCs in vivo 
was also seen with PBMCs
-T
 and T cells (Figure 22E and 22F). In contrast, IFN increased Ido2-
v3 expression in OHSCs (Figure 22G and 22H). Neither Dex nor Gal-9 interacted to accentuate 
Ido2-v3 expression, but Desip diminished the ability of IFNto induce Ido2-v3. 
Combined, in vivo and ex vivo data suggest that the induction and suppression of Ido2-v3 is 
again cell-type specific. Desip induced Ido2-v3 in astrocytes and microglia, but Desip was 
inhibitory in PBMCs and OHSCs.  
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Figure 22. Attenuation of Ido2-v3 expression by Desip. After treatment of mice i.p. with either LPS or Dex (in vivo, A-D) or 
cells/tissue with IFN (ex vivo, E-H) with and without Desip, expression of Ido2-v3 was quantified in A) Hippocampi, B) 
Astrocytes (ACSA-2+ enriched cells), C) Microglia (CD11b+ enriched cells), D) PBMCs, E) PBMC-T, F) T cells (CD90+ 
enriched cells), G) OHSCs ± Dex and H) OHSC ± Gal-9. * p ≤ 0.05 for Ido2-v3 induction by LPS, Dex or IFN;  p ≤ 0.05 for 
the inhibitory effect of Desip within LPS or IFN; p ≤ 0.05 main effect of Desip. 
 
IFN
In vivo, previous work suggested that Desip is anti-inflammatory; for example decreasing 
IFN production by PBMCs (204, 205). As IFN is a potent inducer of Ido1 (62) and Ido2 (206), 
we quantified IFN expression to determine if Desip decreases IFN to control DO expression. 
IFN expression was very low in astrocytes (and not induced, not shown) and not detected in 
OHSCs (not shown). IFN expression was increased by LPS in hippocampi (Figure 23A), 
microglia (Figure 23B) and PBMCs (Figure 23C). Hippocampal and microglial expression was 
attenuated by Desip. These data suggest that diminished Ido1 and Ido2 expression in vivo 
involves decreased IFN. We confirmed this by showing that LPS-induced plasma IFN protein 
was strikingly diminished by Desip (Figure 23C inset). 
Ex vivo, IFN expression was decreased by Desip in PBMCs-T (Figure 23E) but not T 
cells (Figure 23F, albeit T cell expression is ~7.6-fold higher than PBMCs, p<0.05). Thus, in 
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vivo Desip-dependent IFN repression may not occur in T cells per se. As T cells represent ~75% 
of PBMCs, their stable expression is mimicked by stable PBMC expression in vivo. IFN 
expression was not detected in OHSCs. This finding has a critical implication: Desip diminishes 
DO expression ex vivo by directly diminishing activity of IFN. 
TNF, IL-1β and IL-6 expression were also quantified. Expression by PBMCs, microglia 
and astrocytes did not change in response to Desip. In contrast, there was a slight but significant 
increase in TNF and IL-6 by OHSC's in response to Desip (data not shown). Thus, Desip does 
not appear to alter DO expression via diminished pro-inflammatory cytokine expression. 
 
Figure 23. Attenuation of IFN expression by Desip. After treatment of mice i.p. with either LPS or Dex (in vivo, A, B and C) 
or cells with IFN (ex vivo, D and E) with and without Desip, expression of IFN was quantified in A) Hippocampi, B) Microglia 
(CD11b+ enriched cells), C) PBMCs, D) PBMC-T, and E) T cells (CD90+ enriched cells). * p ≤ 0.05 for IFN induction by LPS;  
p ≤ 0.05 for the inhibitory effect of Desip within LPS; p ≤ 0.05 main effect of Desip. 
 
Human PBMC’s 
 Human PBMC’s were treated with IFN with or without Desip to confirm that the finding 
extended beyond rodent models. As for the mouse, there are multiple human IDO1 transcripts, 
we measured two IDO1 transcripts (IDO1-001 and IDO1-005) and one IDO2 transcript (IDO2-
201); all three transcripts encode IDO proteins. IFN increased expression of IDO1-001 (Figure 
24A) and IDO1-005 (Figure 24B). Desip decreased IFN-induced IDO1-001 expression while 
IDO1-005 was numerically lower but statistically unaffected by Desip. IFN also increased 
IDO2-201 expression (Figure 24C), an effect blocked by Desip. 
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Figure 24. Desip decreased IDO1 and IDO2 expression by human PBMCs. After human PBMCs were treated with IFN with 
or without Desip, expression of A) IDO1-001, B) IDO1-005 and C) IDO2-201 was quantified. * p ≤ 0.05 for induction by IFN;  
p ≤ 0.05 for the inhibitory effect of Desip within IFN. 
  
P a g e  | 87 
 
 
4.5 Discussion  
Elevated DO activity (Kynurenine Pathway activation) is linked to both human 
depression and murine depression-like symptomology (14, 15, 43, 180). Although the 
Kynurenine Pathway is associated with depression, there has been no work suggesting that anti-
depressant activity involves modulation of the Kynurenine Pathway. With the incidence of 
depression rising, discovering mechanisms associated with successful anti-depressant therapy is 
vital. The current study determined that the anti-depressant, Desip, was able to decrease DO and 
IFN expression in the brain (hippocampus, microglia and astrocytes) and the periphery 
(PBMCs). Since IFN is the most potent stimulator of Ido1 and Ido2 expression (62, 206), these 
data suggest that Desip can act by limiting IFN production, and thus, diminishing IFN-
dependent Ido1 and Ido2 expression. However, our ex vivo work confirmed that Desip was able 
to directly decrease IFNinduced Ido1 and Ido2 expression by murine PBMC-T, T cells , 
OHSCs and human PBMCs. In this scenario, IFN levels are set by the experimental conditions, 
and thus, Desip decreased IFN activity. Overall, our data suggest for the first time that Desip 
acts by decreasing both IFN levels and IFN activity providing a 2-prong approach to decrease 
DO expression and thus Kynurenine Pathway activation.  
We and others have previously shown that Desip or its precursor imipramine block 
depression-like behaviors of mice (65, 100, 190-195, 207), and that Ido1 is necessary for murine 
depression-like behavior (11, 14, 15, 97). With the current data, we highlight a new putative 
mechanism for Desip's anti-depressant activity: decreasing Ido1 and Ido2 expression within the 
brain and periphery. Determining patient DO-responsiveness to Desip may help to explain the 
variable effectiveness of this drug for alleviating depression symptoms. We cannot rule out that 
neurotransmitters play a role in Desip-mediated decrease in DO expression in vivo, however our 
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ex vivo work support the hypothesis (208) that altered neurotransmitter reuptake is not always 
necessary for a response to Desip. It has been suggested that anti-depressants have 
immunomodulatory actions outside of their ability to inhibit neurotransmitter reuptake (205). 
Thus, it is not unlikely that Desip’s ability to alter Ido expression within the brain and periphery 
is distinct from its reuptake activity. However, confirming that the in vivo and ex vivo OHSC 
responses to Desip on IFN or Ido do not involve neurotransmitter signaling is outside the scope 
of the current manuscript. 
Ido1: Ido1-FL is highly inducible and tightly linked to depression-like behavior in rodent 
models (13, 15, 209) and provided the most consistent Desip responses in the current work. LPS 
increased Ido1-FL expression in the hippocampus, astrocytes, microglia and PBMCs; Desip 
decreased these responses. Although broadly considered a potent enhancer of Ido1 expression in 
vivo, LPS increases the production of multiple factors (cytokines and stress 
hormones/corticosteroids) which may be involved in inflammation-induced behaviors (4, 210). 
Corticosteroid levels are also acutely elevated following LPS administration (211, 212). We 
recently reported that the synthetic glucocorticoid-receptor agonist Dex enhanced the ability of 
IFN to induce Ido1-FL (1), suggesting that stress and inflammation work together to elevate 
central Ido1. We now show that not only can Desip suppress the ability of IFN to induce Ido1, 
Desip can block the synergistic actions of Dex and IFN. Thus, Desip may suppress 
inflammation and stress components of Ido system. Similarly we recently reported that LPS 
increases the expression of galectins within the mouse brain (188). The galectins are a group of 
lectins that have been implicated in several central diseases and neurological disorders (66, 71, 
169, 213, 214). Like, corticosteroids, Gal-9 interacted with IFN to accentuate Ido1-FL 
expression (188). Again, the ability of Gal-9 to enhance Ido induction was suppressed by Desip. 
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Ido1-v1 expression was only minimally increased by LPS. In the hippocampus, the 
magnitude of Ido1-FL induction by LPS was ~500-fold versus ~2-fold for Ido1-v1 indicating 
that Ido1-FL is far more responsive to peripheral inflammation. Astrocytes respond to LPS with 
elevated Ido1-FL and Ido1-v1, whereas microglia respond but only with enhanced Ido1-FL 
expression. These data confirm previous work that murine microglial and astrocyte Ido1 
expression can be similarly induced by IFN (120, 215), but extend those findings to show that 
this is true when quantifying Ido1-FL. We also found that astrocytes had increased Ido1-v1 
expression in response to Dex suggesting that astrocytes play a unique role in the overall 
increase of Ido1 associated with both inflammation- and stress-induced depression-like 
behaviors. These data challenge the dogma that inflammation induced depression-like behaviors 
are solely driven by microglial Ido1-FL induction (15, 216).  
Astrocytes generate the downstream kynurenine metabolite (kynurenic acid, KynA), a 
glutamate and acetylcholine receptor antagonist (39, 118, 217). KynA antagonizes the action of 
quinolinic acid and 3-hydroxykynurenine (glutamate receptor agonists), kynurenine metabolites 
from microglia (118, 123, 144, 218). Thus, astrocyte and microglia responses to inflammation 
lead to elevated levels of neurotransmitter antagonists and agonists (118, 123, 144, 218), 
resulting in what we have termed the 'Confused Brain' (165). Altered microglial and astrocyte 
density and pathology associated with depression reflect this imbalance (218-221). Both 
astrocyte and microglial Ido1-FL expression appear to be sensitive to anti-depressant treatment 
(222, 223), indicating that both aspects of this 'confusion' are alleviated by Desip.  
Possibly the most interesting aspect of these data is the PBMC response. Numerous 
studies have suggested that Ido1 in dendritic (224) and NK cells (225) produce Kyn to modulate 
the peripheral immune system (173, 224, 226, 227). Clinical studies suggest a link between this 
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response and depression (43, 180), connecting peripheral DO activity and MDD. Since Ido1-FL 
expression by PBMCs was increased in response to LPS (in vivo) and IFN (ex vivo) and blocked 
by Desip, our work clearly shows that Desip diminishes both CNS and peripheral DO 
expression. 
Ido2: The primary source of brain Ido2 is neurons (125). As neither Ido2-v1 nor Ido2-v3 
expression in the hippocampus (an area rich with neurons) was increased by LPS, there was no 
response for Desip to inhibit. This suggests that because of low in vivo basal expression, the 
LPS-induced changes in Ido2-v1 within astrocytes and Ido2-v3 in both astrocytes and microglia 
were insufficient to impact total hippocampal Ido2. These data suggest that neuronal Ido2 is 
unaltered by LPS or Desip. LPS-increased Ido2 expression by microglia (Ido2-v1 and Ido2-v3). 
The effect of LPS on microglia was amplified by Desip. This synergy was not found with 
astrocytes, PMBCs or OHSCs. These data suggest a cell-specific response. At this point, 
relatively little is known about Ido2 function, and thus, we can only speculate as to the 
significance of this synergy. However, Ido2 has a role as a negative regulator of Ido1 activity. 
Ido2 competes with Ido1 for heme-binding. In doing so, Ido2 (with its lower enzymatic activity) 
effectively diminishes Kyn production (228). Confirming such an Ido1-inhibitory effect by Ido2-
induction in microglia (which produce QuinA) but not in astrocytes (which produce KynA), 
would support a Desip-induced balance from QuinA (neurotoxic) to KynA (neuroprotective) 
within the brain. Such an action supports our theory that Desip alters Kyn impact via its ability to 
control DO expression. In contrast, addition of IFN to OHSCs is sufficient to elicit a direct and 
detectable Ido2-inducing response. IFN induction of Ido2-v1 is resistant, but Ido2-v3 induction 
is inhibited by Desip. However, the synergy between IFN and Gal-9 on Ido2-v1 expression is 
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blocked by Desip; albeit by undefined cell types. Interpreting the physiological impact of these 
Ido2 responses will require additional studies, but clearly indicate a complex pattern of regulation. 
In the periphery, LPS increased Ido2-v1 and Ido2-v3 expression by PBMCs, responses 
that were attenuated by Desip. The inhibitory effect of Desip was found with PBMC
-T
 and T 
cells. Our data indicate that specific cell types need to be further studied to obtain an accurate 
view of Ido2 regulation in response to inflammation (188), stress (1) or anti-depressants. These 
data further support our conclusion that brain and peripheral Ido1 as well as peripheral Ido2 
expression are modulated by the anti-depressant Desip.  
IFN LPS increased IFN expression in hippocampi, microglia and PBMCs. These 
effects were decreased by Desip, confirming previous reports of the anti-inflammatory potential 
of anti-depressants (204, 205, 229, 230). In contrast, OHSCs did not express IFN clearly 
indicating that Desip was not inhibiting DO expression via diminished IFN production ex vivo. 
The in vivo results suggest that neuroinflammation and concurrent elevation of DOs may be 
tempered by Desip partly via tempering IFN expression (204, 205). However, the OHSC results 
strongly suggest that in the absence of endogenous IFN, Desip is able to directly block the 
ability of added IFN to drive DO expression; the mechanism by which Desip attenuates DO 
expression is currently unknown, but under investigation.  
As OHSCs do not express IFN, it is clear that Desip is not acting ex vivo by suppressing 
endogenous IFN production. However, in vivo, Desip could suppress Ido1 induction by altering 
IFN access to the brain. We found that circulating IFN protein levels are increased by LPS and 
diminished by Desip. IFN enters the brain parenchyma from the circulation via a saturable 
transport system (231). By decreasing circulating IFN, Desip should diminish brain IFN levels 
and thus Ido1 induction. IFN can also be released directly into the brain by PMBCs that have 
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infiltrated the brain. Neutrophils and macrophages are capable of producing IFN and both 
infiltrate the brain following peripheral LPS injection (232, 233). By diminishing IFN 
expression by PBMCs, Desip can diminish IFN-production by PBMCs within the brain and thus 
reduce Ido induction. 
PBMCs: Multiple cell types (monocytes, dendritic cells, NK cells and B cells) respond to 
IFN by increasing Ido1 expression (225, 234-236). Thus, it is likely that several cell types in the 
human and murine PBMC responded to IFN. At this point it is unclear which cell type(s) was 
blocked by Desip. However, due to the near complete inhibition of Ido1expression, it’s clear that 
most cells were responding to Desip. To the best of our knowledge, this is the first report that T 
cells respond to IFN with elevated DO expression, which was diminished by Desip, similar to 
PBMC
-Ts. Similar to murine PBMC’s, IFN increased IDO-001 and IDO2-201 expression in 
human PBMCs, effects completely blocked by Desip. These data indicate that it may be possible 
to use DO regulation by an easily obtainable sample (PBMCs) to characterize anti-depressant 
responsiveness of patients. 
 Conclusion: The inhibitory effect of Desip on gene expression is not a general effect on 
transcription activity. In fact, Desip increased Ido2 expression by microglia. More importantly, 
Desip did not decrease a number of genes in any of our murine models (examples: Haao, Kat2, 
Maoa, Qprt, Tdo2, IL-6 and Ccl5/RANTES). Desip decreased LPS- and IFN-induced 
expression of Ido1 and Ido2 in peripheral cells (PBMCs, PBMCs
-T
 and T cells), resident brain 
cells (astrocytes and microglia), hippocampi and OHSCs; albeit increasing microglial Ido2. As 
elevated DO activity is involved in both human and mouse depression-like behaviors (14, 15, 43, 
180), Desip's ability to block DO expression suggests an additional activity for this anti-
depressant drug (Figure 25). Our data suggest that regulation of DO expression, in particular 
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Ido1-FL, in brain and PBMCs are similarly responsive to this anti-depressant. These pioneering 
data offer insight into both peripheral and brain regulation of Ido1 and Ido2 during 
inflammation- or stressed-induced depression. We propose that monitoring anti-depressant 
responsiveness by assessing DO regulation in a clinically relevant sample, e.g. PBMCs, may be 
suitable for determining drug responsiveness on a case-by-case basis.  
 
Figure 25. Proposed model for Desip blocking Kynurenine Pathway activation in brain and periphery. Multiple studies 
have linked inflammation and stress with major depression in humans and depressive-like behaviors in rodent models. 
Inflammation or stress increase peripheral pro-inflammatory cytokine release (ex. IFN into the circulation, which increases Ido 
expression by PBMCs and most tissues. Either peripheral IFN or infiltrating immune cells capable of producing IFN enter the 
brain to increase Ido expression by both microglia and astrocytes. We've extended this area of research by confirming that Desip 
can act in vivo by 1) blocking peripheral IFN expression as a mechanism to decrease Ido expression by PBMCs, microglia and 
astrocytes. 2) Ex vivo, IFN increases Ido expression by PBMCs (both human and mouse) and synergizes with multiple factors 
(i.e. Dex or Gal-9) to increase the DOs within the brain. As such, we now show that Desip is able to directly block IFN-
dependent Ido induction in both peripheral cells (human and murine PBMCs) and within OHSCs. The later findings suggest that 
3) Desip would also act to directly block DO expression in the periphery and brain by attenuating IFN activity. Kynurenine 
Pathway activation (via the DOs) results in production of additional downstream kynurenine metabolites (kynurenines: quinolinic 
acid: QuinA and kynurenic acid: KynA) that directly alter behavior and immune activity. Thus, Desip is able to modulate DO-
dependent behavior and immune responses indirectly by regulating IFN expression and directly by blocking IFN activity, both 
in the brain and periphery.  
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CHAPTER 5: Conclusion 
5.1 Conclusion 
 This work has shown that complex, intersecting pathways: inflammatory (IFN) and 
either stress (corticosteroids) or galectins (Gal-9), can induce the expression of the rate-limiting 
enzymes of the Kynurenine Pathway in the brain. Furthermore, we confirmed that IFN is a 
major inducer of Ido1 expression in the hippocampus, while multiple inflammatory mediators 
(i.e. IFN, LPS, pI:C) increase hippocampal Ido2 transcript expression, glucocorticoids increase 
Tdo2-FL and Gal-9 increases Tdo2-v1 and Tdo2-v2. In addition, this work emphasizes the 
importance of clarifying the intricate regulation of DO expression in the mouse brain, as the 
interactions are shown to accentuate specific Ido1, Ido2 and Tdo2 transcripts. Finally, we 
discovered that an anti-depressant Desip is able to decrease expression of the DOs within the 
brain and periphery, and interestingly, and this anti-depressant is furthermore able to block the 
synergy between inflammatory mediators and corticosteroids or Gal-9. With the expansive 
population requiring treatment to battle depression, this potential new mechanism for anti-
depressant efficacy could be critical in helping decide first-line choices of anti-depressants for 
inflammation-induced depression in patients. Together, these data confirm that it is crucial to 
understand the connections between overlapping pathways activating the Kynurenine Pathway, 
and this knowledge is directly applicable to effectively treating patients with depression.  
 With the understanding that regulation of the DOs is both complex and potentially is 
unique to the individual, it now becomes crucial to determine ways to specifically block 
expression of individual DO isoforms. One way that could be investigated is the ability of 
CRISPR-Cas9 to block induction of specific DO variants by removing exons found only in the 
inflammation-inducible transcripts, such as eliminating exon 1 from the Ido1 gene so that the 
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Ido1-FL transcript could not be produced. With CRISPR-Cas9 currently being used in clinical 
trials, this technique could potentially benefit a large population drastically affected by 
depression associated with cancer or other neurological/autoimmune conditions. In addition, we 
propose that DO transcript regulation could be controlled by multiple promoters; however, this 
intricate regulation of the DOs is still undefined. We believe that STAT1/5 signaling may be 
involved in initiating transcription of Ido1-FL, so potentially blocking STAT1/5 binding to the 
promoter may be able to block the large induction of Ido1-FL following inflammation x stress 
while not affecting basal Ido1-v1 expression. Finally, creating miRNA or siRNA to 
complementarily bind to specific DO transcripts could also be a way to block the large induction 
of DO transcripts (i.e. Ido1-FL). This could be tailored to blocking these transcripts only in 
specific cell types, but this could be an incredibly useful tool for the future. 
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5.2 Additional Completed work: 
1) Inflammatory mediators and corticosteroids interact to regulate expression of Kynurenine 
Pathway enzymes in neurons, endothelial cells, and microglia 
o Following our previous work showing an interaction between IFN and 
corticosteroids to accentuate Ido1 and Ido2 expression by OHSCs (Chapter 2), I 
treated Neuro2a (neuronal), bEnd.3 (endothelial), C8-B4 (microglia) and 1°-microglia 
with inflammatory mediators and corticosteroids to determine which cell type in the 
brain could be responsible for accentuated Ido1 and Ido2 within the hippocampus. 
We found that IFN increased expression of Ido1 and Ido2 by Neuro2a, C8-B4/1°-
microglia and bEnd.3 cells with Dex accentuating expression of Ido1 and Ido2 by 
endothelial cells but attenuating expression of Ido1 and Ido2 by microglia. Finally, 
Dex increased Tdo2-FL expression only by Neuro2a cells.  
2) Inflammatory mediators and galectins interact to regulate expression of Kynurenine Pathway 
enzymes in neurons, endothelial cells, and microglia 
o Following our previous work showing an interaction between IFN and Gal-9 to 
accentuate Ido1 and Ido2 expression by OHSCs (Chapter 3), I treated Neuro2a 
(neuronal), bEnd.3 (endothelial), C8-B4 (microglia) and 1°-microglia with 
inflammatory mediators and Gal-9 to determine which cell type in the brain could be 
responsible for accentuated Ido1 and Ido2 within the hippocampus. We found that 
IFN increased expression of Ido1 and Ido2 by C8-B4/1°-microglia and both IFN 
and pI:C increased Ido1 and Ido2 expression by bEnd.3 cells. Gal-9 synergized with 
IFN to accentuated Ido1-FL and Ido2-v1 expression by microglia, suggesting that 
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the interaction seen within OHSCs was mediated by changes in microglial Ido1 and 
Ido2 expression. 
3) Expression and regulation of Kynurenine Pathway enzymes in human cancer cells 
o Previously we found that both murine microglia and bEnd.3 cells respond to both 
inflammatory mediators and corticosteroids with IFN x Dex attenuating Ido1 and 
Ido2 expression by microglia and accentuating expression by bEnd.3 cells. We 
wanted to confirm that this work would extend to human cells, and thus, treated 
T98G, SH-SY5Y and THP-1 cells with inflammatory mediators with or without Dex. 
Interestingly, IFN increased Ido1 transcripts expression by T98G, SH-SY5Y and 
THP-1 cells. While Dex synergized with IFN to accentuate Ido1 expression by SH-
SY5Y and THP-1 cells, Dex also synergized with IFN to accentuate Ido2 expression 
by T98G cells. This exciting work again suggests that, similar to the murine cells 
within the brain, regulation of human Ido1 and Ido2 expression is unique and can be 
controlled by both cell-type and transcript-specific changes. 
4) The disparate regulation of Kynurenine Pathway enzymes following inflammation and Desip 
or Fluoxetine treatment in the mouse hippocampus and striatum 
o Similar to Chapter 4, we investigated the ability for both Desip and fluoxetine (Fluox) 
to attenuate LPS-induced Ido1 and Ido2 expression in both the hippocampus and 
striatum. In the striatum and hippocampus, LPS increased Ido1-FL expression (~500-
fold) and excitingly, both Desip and Fluox attenuated this response. We hypothesize 
that the increase of Ido1-FL expression within the striatum and hippocampus is 
mediated by LPS-increased IFN activity and thus, quantified IFN protein levels 
within the plasma and IFN receptor (IFNR) expression within the brain. We found 
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that LPS increased both IFN protein levels within the plasma and IFNR expression. 
Both Desip and Fluox attenuated the LPS-induced IFN protein levels, while Fluox 
decreased expression of IFNR. Together, these data suggest that both anti-
depressants are able to decrease Ido1-FL expression via blocking IFN signaling: by 
decreasing plasma IFN levels and decrease IFNR within the brain.  
5) Collaborative project with Dr. Steelman: The role of Indoleamine-2,3- dioxygenase in 
Theiler's Murine Encephalomyelitis Virus infection 
o In collaboration with Dr. Steelman’s lab, we were interested in determining the role 
of Ido1 and Ido2 in Theiler's Murine Encephalomyelitis Virus (TMEV) infection. We 
infected C57Bl6J wild-type (WT), Ido1 knock-out (KO), Ido1-T Cre and Ido2-T Cre 
mice with TMEV and found that Ido1-KO/-T Cre mice had increased total seizures 
compared to WT mice when watched during the afternoon (2-4 pm), while Ido2-T 
Cre mice had decreased seizures compared to WT mice when watched during the 
morning (8-10am). These data suggest that both Ido1 and Ido2 have important roles 
during viral pathogenesis and clearance.   
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